pyrroles has been researched along with Lung Neoplasms in 333 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (0.60) | 18.7374 |
| 1990's | 2 (0.60) | 18.2507 |
| 2000's | 71 (21.32) | 29.6817 |
| 2010's | 222 (66.67) | 24.3611 |
| 2020's | 36 (10.81) | 2.80 |
| Authors | Studies |
|---|---|
| Das, M; Owonikoko, TK; Padda, SK; Weiss, J | 1 |
| Beke, L; Bhargava, V; Boeckx, A; Brehmer, D; De Lange, D; Diels, G; Fan, Y; Fiore, D; Gilbert, A; Graubert, TA; Gu, J; Gustin, EM; Johnson, A; Keersmaekers, V; Laquerre, S; Lorenzi, MV; Mannens, G; Meerpoel, L; Millar, HJ; Morschhäuser, B; Moy, C; Nys, T; Packman, K; Pande, V; Pastore, F; Philippar, U; Rai, S; Safabakhsh, P; Schepens, W; Sun, W; Thuring, JW; van Heerde, E; Verbist, B; Verhulst, T; Viellevoye, M; Vinken, P; Walker, D; Wu, T; Zhou, L | 1 |
| Abraham, I; Chioda, M; Deniz, B; Huang, H; MacDonald, K; Moran, D; Onyekwere, U | 1 |
| He, KM; Pu, JT; Teng, ZY; Wu, YF; Zhang, DG; Zhang, T | 1 |
| Kida, Y; Koshikawa, N; Lin, J; Nagase, H; Shinozaki, Y; Takenaga, K; Tsuji, K; Watanabe, T; Yamamoto, S | 1 |
| Cai, K; Feng, Q; Gou, S; He, T; Hu, Y; Liu, G; Wang, L | 1 |
| Féliz, L; Gutierrez, M; Iannotti, NO; Ji, T; Lihou, CF; Saleh, M; Silverman, IM; Smith, DC; Subbiah, V; Tian, C | 1 |
| Ding, X; Li, S; Liu, C; Yang, H; Yuan, W; Zhu, L | 1 |
| Amin, M; Bagegni, NA; Baggstrom, MQ; Devarakonda, S; Gao, F; Kraft, K; Liang, C; Morgensztern, D; O-Toole, M; Park, H; Ratner, L; Selvaggi, G; Wang-Gillam, A; Waqar, SN | 1 |
| Beelen, A; Curd, L; Goti, V; Horton, JK; Li, C; Sale, M; Tao, W | 1 |
| Chen, J; Huang, XR; Lan, HY; Lee, CS; Li, M; Lian, GY; Mak, TS; Tang, PM; Wan, Y; Wang, QM; Wang, ZY; Yu, XQ; Zhang, J | 1 |
| Addeo, A; Alborelli, I; Calgua, B; Fernandez, E; Früh, M; Haefliger, S; Holer, L; Jermann, PM; Joerger, M; Mach, N; Mark, M; Mauti, L; Rothschild, SI; Savic-Prince, S; Schneider, M; Waibel, C | 1 |
| He, J; Luo, L; Xu, S; Yang, F; Zhu, W | 1 |
| Bhatt, DL; Chen, YH; Connell, CA; Curtis, JR; Gómez-Reino, JJ; Gunay, LM; Menon, S; Sugiyama, N; Vranic, I; Wang, C; Wu, J; Yamaoka, K | 1 |
| Jannath, KA; Kim, KB; Park, DS; Saputra, HA; Shim, YB | 1 |
| Bender, S; Boix, O; Cassier, PA; Cathomas, R; Cho, BC; Ellinghaus, P; Gajate, P; Grevel, J; Joerger, M; Navarro, A; Nogai, H; Nogova, L; Ocker, M; Park, SH; Penel, N; Rajagopalan, P; Richly, H; Sayehli, CM; Schostak, M; Schuler, M; Soo, RA; Tai, D | 1 |
| Adler, S; Aljumaily, R; Antal, JM; Beck, JT; Boccia, RV; Bulat, I; Chiu, VK; Csoszi, T; Domine Gomez, M; Dragnev, KH; Hamm, JT; Hanna, W; Hart, LL; Hoyer, RJ; Hussein, MA; Lai, AY; Lowczak, A; Maglakelidze, M; Malik, RK; Morris, SR; Nikolinakos, P; Owonikoko, TK; Richards, DA; Roberts, PJ; Rocha Lima, CM; Sawrycki, P; Schuster, SR; Sorrentino, JA; Weiss, JM; Yang, Z | 1 |
| Balansky, R; De Flora, S; Izzotti, A; La Maestra, S; Micale, RT; Pulliero, A | 1 |
| Auyeung, AB; Betancourt, T; Beztsinna, N; Bonnet, S; Gildner, MB; Hilt, ST; Hudnall, TW; Kornienko, A; Lameijer, LN; Le Dévédec, SE; Leger, DY; Liagre, B; Ramu, V; Sol, V; van Rixel, VHS; Yildiz, T | 1 |
| Han, KH; Jeong, IH; Jin, JO; Kim, MJ; Kwak, M; Lee, PC; Lee, TH; Park, MS | 1 |
| Avestan, MS; Damghani, T; Edraki, N; Firuzi, O; Khoshneviszadeh, M; Mashayekh, K; Pirhadi, S; Sharifi, S | 1 |
| Aguirre, AJ; Almonte, C; Bonneau, R; Bulatovic, M; Castro, DM; Chen, T; Christensen, CL; Deng, J; Diskin, B; Donaghue, J; Dowling, CM; Dries, R; Freeman, GJ; Gray, NS; Hammerman, PS; Han, H; He, Z; Huang, Q; Jani, K; Kaelin, WG; Kersbergen, A; Kwiatkowski, N; Labbe, KE; Leggett, A; Li, F; Li, S; Miller, G; Oser, MG; Pan, Y; Papadopoulos, E; Pyon, V; Quinn, M; Rabin, AR; Ranieri, M; Rothenberg, E; Silver, H; Sundberg, B; Sutherland, KD; Sviderskiy, VO; Thakurdin, C; Velcheti, V; Wang, ES; Wong, KK; Yang, A; Yin, Y; Yuan, GC; Zhang, H; Zhang, T; Zhang, X | 1 |
| Si, X; Song, P; Wang, H; Yang, D; Zhang, L; Zhang, X | 1 |
| Jia, X; Liu, X; Wang, L; Wei, A; Zhang, K | 1 |
| Chen, ZS; Lei, ZN; Lin, L; Sun, L; Teng, QX; Wang, G; Wang, JQ; Wu, ZX; Yang, Y; Zou, C | 1 |
| Chen, S; Duan, P; Ren, Y | 1 |
| Das, S; Say, EAT; Sioufi, K | 1 |
| Ilhan, R; Ince-Yardimci, A; Kara, P; Kirmizibayrak, PB; Kivrak, E; Yilmaz, S | 1 |
| Abergel, RJ; An, DD; Ansoborlo, C; Gauny, SS; Karsunky, H; Lakes, AL; Liang, BH; McKnight, KD; Rees, JA | 1 |
| Chuang, EY; Jheng, PR; Lu, KY; Lu, LS; Mi, FL; Rethi, L | 1 |
| Deng, K; Ding, C; Hong, B; Li, H; Lin, WC; Liu, XL; Lui, VWY; Lv, XT; Shi, WH; Yin, YP | 1 |
| Alhudaithi, SS; Almuqbil, RM; Bielski, ER; Bos, PD; da Rocha, SRP; Du, W; Sunbul, FS; Zhang, H | 1 |
| Fu, H; Fu, L; Li, Y; Lou, L; Quan, H; Zhang, M | 1 |
| Dominici, C; Masson, JY; Raynal, NJ; Richard, S; Sesma-Sanz, L; Sgarioto, N; Yu, Z | 1 |
| Chow, Z; Evers, BM; Johnson, J; Lee, E; Rychahou, P; Weiss, HL | 1 |
| Aschenbrenner, DS | 1 |
| Csőszi, T; Dómine Gómez, M; Horton, JK; Jaal, J; Kudaba, I; Malik, RK; Nikolov, K; Radosavljevic, D; Subramanian, J; Xiao, J | 1 |
| Fan, D; Qu, S; Yang, Y; Yu, S | 1 |
| Chai, Y; Chen, H; He, Y; Huang, R; Li, W; Li, Y; Ma, L; Xia, Z; Yu, Q; Zhou, X | 1 |
| Anderson, I; Csőszi, T; Edenfield, W; Feinstein, TM; Ferrarotto, R; García-Campelo, MR; Johnson, JM; Kalmadi, S; Lammers, PE; Malik, RK; Medgyasszay, B; Morris, SR; Pritchett, Y; Sanchez-Hernandez, A | 1 |
| Li, J; Xu, H | 1 |
| Burghardt, I; Lindemann, JP; Regli, L; Roth, P; Rushing, EJ; Sahm, F; Schuknecht, B; von Deimling, A; Weller, M | 1 |
| Dai, B; Liu, R; Ma, Y; Wang, W; Zhan, Y; Zhang, D; Zhang, Y | 1 |
| Aerts, JG; Bezemer, K; Dammeijer, F; Hegmans, JP; Hendriks, RW; Kaijen-Lambers, ME; Lievense, LA; van Hall, T; van Nimwegen, M | 1 |
| Chung, MH; Hahm, KB; Han, YM; Jeong, M; Ko, KH; Kwon, CI; Park, JM | 1 |
| Carillio, G; Costanzo, R; Daniele, G; Manzo, A; Montanino, A; Morabito, A; Normanno, N; Perrone, F; Piccirillo, MC; Rocco, G; Sandomenico, C | 1 |
| Kim, C; Matsuyama, A; Mutsaers, AJ; Woods, JP | 1 |
| Adelaiye-Ogala, R; Arisa, S; Arrington, J; Buck, M; Budka, J; Chintala, S; Ciamporcero, E; Damayanti, NP; Draetta, GF; Elbanna, M; Ferris, M; Hancock, B; Hollenhorst, P; Hsu, CC; Irudayaraj, J; Keilhack, H; Kota, J; McCarthy, BP; Miles, KM; Orillion, A; Persohn, SA; Pettazzoni, P; Pili, R; Radovich, M; Seshadri, M; Shen, L; Tao, WA; Territo, PR; Zang, Y | 1 |
| 'Aho, T; Armitage, JN; Eisen, T; Fife, K; Klatte, T; Matakidou, A; Riddick, AC; Sachdeva, M; Stewart, GD; Welsh, SJ | 1 |
| Filip-Psurska, B; Kutner, A; Maj, E; Milczarek, M; Psurski, M; Wietrzyk, J | 1 |
| Gu, Y; Hong, H; Lei, YY; Lu, CG; Sheng, SY; Tang, YY; Zhang, YQ; Zou, JY | 1 |
| Jia, W; Liu, Y; Min, L; Qiankun, Z; Sun, W; Wang, WH; Wu, D; Yang, H; Yang, Y; Zhang, H; Zhang, J; Zhang, Y | 1 |
| Banskota, S; Chaudhary, P; Dahal, S; Gautam, J; Jeong, BS; Kang, HE; Kim, DG; Kim, JA; Lee, IH; Nam, TG | 1 |
| Bender, S; Boemer, U; Collin, MP; Ellinghaus, P; Grünewald, S; Héroult, M; Hess-Stumpp, H; Ince, S; Kneip, C; Kopitz, C; Lustig, K; Mumberg, D; Politz, O; Thuss, U; Ziegelbauer, K; Zopf, D | 1 |
| Chiang, CW; Chuang, EY | 1 |
| Feng, T; Li, P; Peng, L; Qin, S; Wan, J; Yuan, P; Zhang, L; Zhao, T | 1 |
| Maeda, A; Nakata, M; Nojima, Y; Okita, R; Saisho, S; Shimizu, K | 1 |
| Cámara-Fernández, N; Cartagena-Albertus, JC; Moise, A; Montoya-Alonso, JA; Moya-García, S | 1 |
| Bourcier, ME; Vinik, AI | 1 |
| Kim, H; Nagata, Y; Shoji, S; Terachi, T; Uchida, T; Usui, Y | 1 |
| Bora-Singhal, N; Chellappan, SP; Kroeger, J; Laklai, H; Singh, S | 1 |
| Bravo, J; Cañueto, J; de Unamuno, P; Mir-Bonafé, JM | 1 |
| Ardizzoni, A; Bella, MA; Porzio, R; Rossi, G | 1 |
| Armand, JP; Bahleda, R; Baselga, J; Berman, D; Calvo, E; Felip, E; Hanna, N; Harbison, CT; Herbst, RS; Kurland, JF; Laurie, SA; Park, JS; Pathak, AK; Shepherd, FA; Soria, JC; Vakkalagadda, B; Zhang, S | 1 |
| Bydlowski, SP; Chierice, GO; Ferreira, AK; Filho, OM; Freitas, VM; Levy, D; Maria, DA; Rici, RE; Ruiz, JL | 1 |
| Hou, T; Lee, SM; Li, P; Li, S; Li, Y; Pan, P; Shen, M; Yu, H; Zhang, L; Zhou, S | 1 |
| Devarakonda, S; Gopalan, PK; Govindan, R; Waqar, SN; Williams, K | 1 |
| Feldman, DR; Ginsberg, MS; Hsieh, JJ; Jia, X; Molina, AM; Motzer, RJ; Patil, S; Velasco, S | 1 |
| Chai, ZT; Gao, DM; Kong, LQ; Lu, L; Sun, HC; Tang, ZY; Wang, L; Wang, WQ; Wu, WZ; Xu, HX; Zhang, JB; Zhang, W; Zhu, XD; Zhuang, PY | 1 |
| Asmar, L; Boehm, KA; Bradie-Muller, SJ; Gluck, L; Mueller, SE; Reynolds, C; Spira, AI; Zhan, F | 1 |
| Baas, P; Blumenschein, GR; Butts, CA; Chao, RC; Chmielowska, E; Gao, F; Gridelli, C; Groen, HJ; Grossi, F; Harmon, C; Juhasz, E; Selaru, P; Socinski, MA; Tye, L; Usari, T; Williams, JA | 1 |
| Bahleda, R; Escudier, B; Gueutin, V; Izzedine, H; Rouvier, P; Soria, JC; Varga, A | 1 |
| Ishida, R; Kobayashi, H; Nishikimi, T; Tsuzuki, T; Yamada, H; Yamauchi, Y; Yokoi, K; Yoshida, S | 1 |
| Blais, N; Camidge, DR; Chao, RC; Chow, LQ; Diab, SG; Jonker, DJ; Laurie, SA; Ruiz-Garcia, A; Soulières, D; Thall, A; Zhang, K | 1 |
| Ding, J; Li, X; Meng, LH; Tong, LJ | 1 |
| Bi, H; Chen, J; Hou, J; Liu, B; Liu, D; Liu, J; Shi, H; Wen, X; Yuan, J; Yue, L; Zhang, C; Zhang, X | 1 |
| Han, BH; Huang, JQ; Jiang, LY; Li, SQ; Liu, YR; Yao, YH; Zhang, JL; Zhang, W; Zhao, YZ; Zhu, W | 1 |
| Dell'Aquila, E; Frezza, AM; Grasso, RF; Guida, FM; Lanzetta, G; Santini, D; Silletta, M; Silvestris, N; Tonini, G; Venditti, O; Vincenzi, B | 1 |
| Adams, JW; Berger, MS; Chiappori, A; Edelman, MJ; Haura, EB; Malik, S; Northfelt, DW; Rosen, P; Van Echo, DA; Williams, C | 1 |
| Cho, JY; Choi, SW; Heo, JN; Kim, SH; Lee, H; Lee, J; Lee, SY; Ryu, BJ; Yeon, JT | 1 |
| Fujimoto, K; Momose, H; Morizawa, Y; Oyama, N; Takada, S; Toyoshima, Y | 1 |
| Gandhi, L; Heist, RS; Hodgson, L; Otterson, GA; Socinski, MA; Stinchcombe, TE; Villalona-Calero, MA; Vokes, EE; Wang, X; Watson, P | 1 |
| Baudin, E; Bonichon, F; Borget, I; Brassard, M; Chougnet, CN; Claude-Desroches, M; de la Fouchardière, C; Do Cao, C; Giraudet, AL; Leboulleux, S; Massicotte, MH; Schlumberger, M | 1 |
| Yaqub, F | 1 |
| Habuchi, T; Inoue, T; Maita, S; Narita, S; Numakura, K; Saito, M; Satoh, S; Tsuchiya, N; Yonese, J; Yuasa, T | 1 |
| Follana, P; François, E; Gugenheim, J; Saada, E; Saint Paul, MC | 1 |
| Ahn, H; Cho, YM; Hong, JH; Jeong, IG; Kim, CS; Lee, JL; Song, C; Song, SH; You, D | 1 |
| Bernstein, E; Burrows, F; Gitlitz, BJ; Milne, G; Otterson, GA; Santos, ES; Syto, M; Zaknoen, S | 1 |
| Casserly, L; Gupta, R; Neenan, T; Quintyne, KI | 1 |
| Chen, X; Li, Y; Meng, Q; Sun, H; Xu, P; Yin, Q; Yu, H; Zhang, Z | 1 |
| Albert, I; Ao-Baslock, A; Berger, MS; Blakely, LJ; Kazarnowicz, A; Kovacs, P; Langer, CJ; Moezi, MM; Pajkos, G; Pathak, AK; Ross, HJ; Schnyder, J; Schreeder, MT; Somfay, A; Zatloukal, P | 1 |
| Bianco, C; Bianco, R; Ciardiello, F; Cipolletta, A; D'Amato, C; D'Amato, V; De Placido, S; Di Mauro, C; Formisano, L; Fulciniti, F; Marciano, R; Nappi, L; Raimondo, L; Rosa, R; Servetto, A; Veneziani, BM | 1 |
| Alfonso, H; Lake, RA; Musk, AW; Nowak, AK; Olsen, N; Robinson, BW; Robinson, C; Walsh, A; Woo, S | 1 |
| Dervan, PB; Raskatov, JA; Szablowski, JO | 1 |
| Nishiyama, T; Niwa, N; Ozu, C; Saito, S; Yagi, Y | 1 |
| Chen, Y; Hong, S; Luo, S; Tan, M; Wang, S; Zhang, L | 1 |
| de Mayolo, JA; Edelman, MJ; Evans, TL; Feliciano, J; Fidler, MJ; Keresztes, R; Medeiros, M; Otterson, G; Rogers, JS; Sanborn, RE; Schneider, BJ; Sequist, LV; Tan, MT; Yang, Y; Zaknoen, SL | 1 |
| Abdullaev, Z; Beadling, C; Berman, A; Carter, CA; Corless, CL; Doyle, A; Giaccone, G; Guha, U; Kelly, R; Killian, K; Lau, CC; Liewehr, DJ; Lopez-Chavez, A; Meltzer, PS; Morrow, B; Pack, S; Raffeld, M; Rajan, A; Sandler, A; Steinberg, SM; Szabo, E; Thomas, A; Wang, Y; Warrick, A; Xi, L | 1 |
| Balansky, R; D'Agostini, F; De Flora, S; Ganchev, G; Iltcheva, M; La Maestra, S; Micale, RT; Nikolov, M; Steele, VE | 1 |
| Baggstrom, M; Bogart, J; Crawford, J; Graziano, SL; Gu, L; Masters, GA; Miller, AA; Otterson, GA; Pang, HH; Ready, NE; Thomas, SP; Vokes, EE | 1 |
| Leighl, NB | 1 |
| Bos, MM; De Santis, M; Eichelberg, C; Fischer von Weikersthal, L; Flörcken, A; Freier, W; Goebell, PJ; Gottstein, D; Hauswald, K; Indorf, M; Lerchenmüller, C; Los, M; Michel, MS; Pahernik, S; Schenck, M; Schirrmacher-Memmel, S; Staehler, M; van Arkel, C; Vervenne, WL; Zimmermann, U | 1 |
| Thoma, C | 1 |
| Baba, E; Iguchi, A; Kusaba, H; Sagara, K; Sakamoto, N; Takayoshi, K; Uchino, K | 1 |
| Hohenberger, P; Jakob, J; Kasper, B; Ronellenfitsch, U; Simeonova, A; Wenz, F | 1 |
| Kamata, S; Yoshinaga, A | 1 |
| Albiges, L; Escudier, B | 1 |
| Altavilla, A; Boni, L; Bracarda, S; Camerini, A; Derosa, L; Di Lorenzo, G; Escudier, B; Galli, L; Iacovelli, R; Longo, F; Morelli, F; Porta, C; Procopio, G; Rizzo, M; Rossi, M; Santoni, M; Sisani, M | 1 |
| Shih, JY; Wu, H; Yang, JC | 1 |
| Han, J; Hoff, BH; Kaspersen, SJ; Sundby, E | 1 |
| Chen, Y; Qiu, S; Tu, X; Wang, D; Wu, R; Zhuang, J | 1 |
| Fujisawa, M; Harada, K; Imai, S; Miyake, H | 1 |
| Fujikawa, A; Moriyama, M; Namura, K; Ota, J; Otake, S; Sawada, T | 1 |
| Billingham, LJ; Buller, R; Carr, TH; Crack, LR; Hollingsworth, SJ; Middleton, G; Popat, S; Swanton, C; Walker, I; Wherton, D | 1 |
| Basso, U; Maruzzo, M | 1 |
| Bracarda, S | 1 |
| Barett, C; Bikas, A; Burman, KD; Clark, BG; Desale, S; Gandhi, R; Jelinek, JS; Kundra, P; Mete, M; O'Keefe, K; Wartofsky, L; Wexler, JA; Wray, L | 1 |
| Abdelraouf, F; Baas, P; Hasan, B; Menis, J; O'Brien, M; Popat, S; Smit, E; Surmont, VF; van Meerbeeck, JP | 1 |
| Chang, CC; Chen, RJ; Chiou, HY; Hsieh, CC; Hsieh, CI; Lien, YC; Tai, CJ; Tzao, C; Wang, CK; Wu, CH; Wu, HC | 1 |
| Hashemian, Z; Khayamian, T; Saraji, M; Shirani, MP | 1 |
| Bogart, JA; Crawford, J; Gu, L; Pang, HH; Ready, NE; Salama, JK; Schild, SE; Vokes, EE; Wang, X | 1 |
| Bortlicek, Z; Buchler, T; Dusek, L; Fiala, O; Honzirkova, M; Kubackova, K; Melichar, B; Pavlik, T; Poprach, A; Slaby, O; Svoboda, M; Veskrnova, V; Vyzula, R; Zemanova, M | 1 |
| Almaden, C; Bailey, S; Baxi, S; Behenna, D; Cheng, H; Cho-Schultz, S; Dalvie, D; Dinh, DM; Edwards, MP; Feng, JL; Ferre, RA; Gajiwala, KS; Hemkens, MD; Jackson-Fisher, A; Jalaie, M; Johnson, TO; Kania, RS; Kath, JC; Kephart, S; Lafontaine, J; Liu, KK; Liu, Z; Lunney, B; Matthews, J; Murray, BW; Nagata, A; Nair, SK; Niessen, S; Ornelas, MA; Orr, ST; Pairish, M; Planken, S; Ren, S; Richter, D; Ryan, K; Sach, N; Shen, H; Smeal, T; Solowiej, J; Sutton, S; Tran, K; Tseng, E; Vernier, W; Walls, M; Wang, S; Weinrich, SL; Xin, S; Xu, H; Yin, MJ; Zhou, R; Zientek, M | 1 |
| Bao, Y; Chen, Q; Feng, W; Guo, H; Lu, Y; Sun, X; Wang, X | 1 |
| Choi, EK; Jeong, SY; Kim, J; Kim, N; Koo, HJ; Lee, JS; Lee, M; Woo, CW | 1 |
| Cox, NI; Lai, SC; Mu, D; Phelps, CA; Poddar, A; Talbot, C; Wood, LW | 1 |
| Bao, YX; Deng, HB; Deng, LL; Guo, Y; Lu, CL; Lu, X; Zhao, XD | 1 |
| Aebischer, B; Akboga, MK; Akdamar, G; Alcalay, RN; Álvarez-Pérez, S; Aydogdu, S; Balci, KG; Barcaro, G; Bišová, K; Blanco, JL; Brewer, SH; Caruthers, SD; Ceylan, O; Chadwick, JA; Chang, DD; Che, JM; Chen, QQ; Chen, W; Chen, Z; Chung, M; Chung, W; Colecraft, HM; Coteli, E; Dogan, H; Dong, S; Elsig, S; Fahn, S; Fang, XJ; Feng, MG; Fenlon, EE; Floyd, KT; Fokdal, L; Ford, B; Fortunelli, A; Freudenberg, R; Gan-Or, Z; García, ME; Gillham, C; Giovannelli, D; Goertz, RS; Gulati, V; Haie-Meder, C; Hao, YY; Hatano, K; Hines, KJ; Hines, SM; Hirakawa, H; Hoskin, P; Hu, JH; Huang, P; Huang, Y; Hubicka, U; Inoue, Y; Ishii, N; Janssen, PM; Jin, Z; Johnson, A; Jürgenliemk-Schultz, I; Kaineder, K; Kamei, K; Kang, U; Karatas, F; Kash, TL; Katayama, Y; Keupp, J; Kirisits, C; Kisacik, H; Kodama, K; Kotzerke, J; Kryczyk, A; Kuhness, D; Kuo, S; Lanza, GM; Le Bris, N; Levin, DE; Levy, OA; Li, B; Li, H; Li, X; Liang, GD; Liang, Y; Liao, RQ; Lin, JT; Lindegaard, JC; Liong, C; Liu, B; Liu, C; Liu, GH; Liu, L; Liu, Q; Liu, X; Lowe, J; Lowery-Gionta, EG; Ma, YH; Maden, O; Mankad, V; Marder, KS; Marshall, SA; Martínez-Nevado, E; Maucksch, U; Mazeron, R; Mazzone, CM; Mazzoni, P; Mezricky, D; Mizokami, Y; Naumann, A; Navarro, M; Netzer, FP; Neurath, MF; Nie, Q; Oliva, P; Ozeke, O; Peláez, T; Pfeifer, L; Pleil, KE; Pomp, S; Pötter, R; Puckerin, AA; Rafael-Fortney, JA; Raman, SV; Rastogi, N; Řezanka, M; Řezanka, T; Rinker, JA; Rouleau, GA; Runge, R; Sahin, MD; Sakai, A; Schmieder, AH; Schmitz, AJ; Schultz, EJ; Šegedin, B; Sementa, L; Shen, Y; Shiotsuki, I; Shirahama, M; Staley, J; Starovoytov, V; Sterrer, M; Strobel, D; Sturdza, A; Subramanyam, P; Surnev, S; Swager, SA; Taeymans, J; Tan, H; Tan, LT; Tanderup, K; Temizhan, A; Terao, T; Thiele, TE; Tran, T; Tucker, MJ; Vetriani, C; Vítová, M; Wang, JP; Wang, L; Wang, M; Wang, X; Waters, CH; Weng, SX; Wickline, SA; Wildner, D; Wodarcyk, AJ; Wolf, P; Wu, L; Wu, YL; Wunderlich, G; Xiong, L; Xu, P; Yang, GS; Yang, XN; Yang, Y; Yayla, C; Ying, SH; Zachleder, V; Zhang, XG; Zhang, XK; Zhang, Y; Zheng, JY; Zhong, WZ; Zhu, J; Zhu, YJ; Żmudzki, P | 1 |
| Clausse, M; Coulier, B; De Wulf, S; Frognier, R; Rezazadeh Azar, A; Van Cutsem, O | 1 |
| Liu, K; Ma, J; Wu, K; Xu, Z; Zhao, Z | 1 |
| Ji, SM; Li, JY; Li, L; Lu, W; Mou, ZZ; Ren, YP; Wang, LJ; Yuan, Y; Zhou, SP; Zhou, TY | 1 |
| Chen, G; Li, YH; Wang, DC; Wang, LC; Wang, LJ; Zhao, YX; Zhao, ZF | 1 |
| Grünwald, V; Kalanovic, D; Lin, X; Simantov, R | 1 |
| Cho, Y; Goh, SH; Han, JY; Jeon, S; Lee, H; Seo, JS | 1 |
| Aigner, F; Heidegger, I; Horninger, W; Pichler, R; Tulchiner, G | 1 |
| Babu, N; Balaji, SA; Chang, X; Chatterjee, A; Datta, KK; Gowda, H; Izumchenko, E; Nanjappa, V; Pandey, A; Patil, AH; Prasad, TS; Puttamallesh, VN; Radhakrishnan, A; Raja, R; Rangarajan, A; Renuse, S; Sahasrabuddhe, NA; Sidransky, D; Solanki, HS; Syed, N | 1 |
| Li, T; Luo, Z; Wang, C; Wang, H; Wang, L; Zhang, S; Zhang, X | 1 |
| Campanario, R; Juárez, A; Saiz, R; Soto, M | 1 |
| Munakata, S; Shiba, M; Takayama, H; Takeda, K; Wang, C | 1 |
| Fujioka, Y; Fujita, H; Gomori, A; Harada, N; Haruma, T; Hashimoto, A; Inada, M; Ito, K; Kataoka, Y; Matsuo, K; Oda, N; Sakuragi, M; Suzuki, T; Tanaka, K; Yamamoto-Yokoi, H; Yonekura, K | 1 |
| Bilecz, A; Bridgeman, VL; Daley, F; Dome, B; Dvorak, HF; Foo, S; Frentzas, S; Gore, M; Hegedus, B; Hoetzenecker, K; Kerbel, RS; Kostaras, E; Kuczynski, EA; Larkin, J; Nathan, MR; Paku, S; Renyi-Vamos, F; Reynolds, AR; Schweiger, T; Vasudev, NS; Vermeulen, PB; Wan, E | 1 |
| Chang, H; Kim, HS; Kim, JW; Lee, JS; Moon, SU; Sung, JH | 1 |
| Guo, Q; Li, Y; Wang, G; Xu, J; Zhang, C; Zhang, J; Zhang, Y; Zheng, T | 1 |
| Hao, F; Li, J; Lu, W; Wang, L; Wang, S; Xue, J; Zhou, T; Zhu, X | 1 |
| Li, H; Li, J; Wu, X; Zhang, X; Zhang, Y; Zheng, G | 1 |
| Fitzgerald, SD; Harrison, T; Needle, D; Patterson, J; Thompson, KA | 1 |
| Kong, W; Liu, G; Liu, X; Qu, J; Suo, S; Wu, G; Xu, J; Zhang, J | 1 |
| Baggstrom, MQ; Baker, S; Crawford, JA; Edelman, MJ; Feliciano, J; Gu, L; Hahn, O; Novotny, P; Socinski, MA; Stinchcombe, TE; Vokes, EE; Wang, XF | 1 |
| Cuccarese, MF; Dubach, JM; Engblom, C; Garris, C; Miller, MA; Pfirschke, C; Pittet, MJ; Weissleder, R | 1 |
| Adeduntan, R; Antoni, D; Noël, G; Paix, A; Waissi, W | 1 |
| Albiges, L; Champiat, S; Danlos, FX; Lambotte, O; Le Pavec, J; Marabelle, A; Michot, JM; Pradere, P | 1 |
| Falkowski, S; Jagodzińska-Mucha, P; Klimczak, A; Koseła-Paterczyk, H; Kozak, K; Rogala, P; Rutkowski, P; Świtaj, T; Wągrodzki, M; Ługowska, I | 1 |
| Asselineau, J; Bournaud-Salinas, C; Caron, P; Catargi, B; Daste, A; de la Fouchardière, C; Delord, JP; Digue, L; Do Cao, C; Doussau, A; Gimbert, A; Klein, M; Nicolli-Sire, P; Pedenon, D; Picat, MQ; Pouessel, D; Ravaud, A; Rodien, P; Wemeau, JL | 1 |
| Gettinger, S | 1 |
| Harisinghani, MG; Iliopoulos, O; McDermott, DF; McGovern, FJ; Michaelson, MD; Oliva, E | 1 |
| Socinski, MA | 1 |
| Jin, H; Lin, Y; Lu, G; Snagaski, B; Xiao, H; Yang, CS; You, H | 1 |
| Basso, U; Bedogni, A; Brunello, A; Saia, G; Scaglione, D | 1 |
| Beuselinck, B; Pans, S; Schöffski, P; Wolter, P | 1 |
| Dong, WL; Miao, JY; Wu, LL; Zhao, BX; Zheng, LW | 1 |
| Kamposioras, K; Mauri, D; Panou, C; Tsali, L; Valachis, A | 1 |
| Asemissen, AM; Keilholz, U; Knoedler, M; Miller, K; Schmittel, A; Steiner, U; Thiel, E; Zimmermann, K | 1 |
| Borgman, CL; Brandstetter, KA; Chirieac, LR; Gandhi, L; Li, D; McDermott, U; McNamara, KL; Padera, RF; Settleman, JE; Wong, KK | 1 |
| Connault, J; Durant, C; Pistorius, MA; Planchon, B; Saint-Jean, M | 1 |
| Horn, L; Sandler, AB | 1 |
| Ames, RY; Brannigan, BW; Erlander, MG; Greninger, P; Haber, DA; Iafrate, AJ; Lee, DY; Lucien, L; Ma, XJ; Maheswaran, S; McCutcheon, K; McDermott, U; Milano, R; Settleman, J; Sharma, SV; Stubbs, H; Tam, A; Ulkus, LE | 1 |
| Dudek, AZ; Franklin, M; Murthaiah, PK; Truskinovsky, AM | 1 |
| Desar, IM; Mulder, SF; Mulders, PF; Stillebroer, AB; van der Graaf, WT; van Herpen, CM; van Spronsen, DJ | 1 |
| Cikotiene, I; León, LG; Padrón, JM; Pudziuvelyte, E; Ríos-Luci, C | 1 |
| Arregi, A; Azpiroz, A; Beitia, G; Garmendia, L; Vegas, O | 1 |
| Dziadziusko, R; Fennell, D; Gridelli, C; Lacombe, D; Pallis, AG; Serfass, L; van Meerbeeck, JP; Welch, J | 1 |
| Park, CY | 1 |
| Azzoli, CG; Calcutt, MW; Janjigian, YY; Kris, MG; Krug, LM; Lee, W; Miller, VA; Rizvi, NA; Senturk, E | 1 |
| Beynat, C; Coudert, B; Diaz, P; Favier, L; Ghiringhelli, F; Ladoire, S | 1 |
| Burrell, RA; Swanton, C | 1 |
| Atkins, J; Brahmer, J; Burgess, R; Chao, R; Govindan, R; Novello, S; Pallares, C; Rosell, R; Scagliotti, GV; Selaru, P; Socinski, MA; Tye, L; Wang, E | 1 |
| Dikilitas, M; Er, O; Karaca, H; Lale, A; Ozkan, M | 1 |
| Edeline, J; Laguerre, B; Patard, JJ; Rolland, Y | 1 |
| Agata, N; Akaza, H; Fujimoto, H; Hasegawa, Y; Houk, B; Miki, T; Mugiya, S; Naito, S; Niwakawa, M; Nonomura, N; Shinohara, N; Takahashi, M; Tomita, Y; Uemura, H; Yuasa, T | 1 |
| Faivre, S; Hammel, P; Raymond, E; Ruszniewski, P | 1 |
| Dianov, GL; Fanta, M; Freschauf, GK; Grassot, JM; Hall, DG; Mani, RS; Mereniuk, TR; Virgen, CA; Weinfeld, M | 1 |
| Carli, P; Ceravolo, R; Donach, M; Faggioni, G; Farina, M; Furini, L; Lombardi, G; Nicoletto, O; Pastorelli, D; Zovato, S; Zustovich, F | 1 |
| Costero, O; Martinez-Ara, J; Picazo, ML; Romero, S; Selgas, R; Zamora, P | 1 |
| Cataruozolo, PE; Chuang, E; Collier, M; Gowland, PA; Huang, X; Kern, KA; Kozloff, M; Miller, K; Starr, A; Verkh, L | 1 |
| Kolb, MM; Kozloff, MF; Samant, M; Scappaticci, FA; Socinski, MA | 1 |
| Aparicio, LM; Calvo, OF; López, MR; Vázquez, DD | 1 |
| Guillén-Ponce, C; Mena, AC; Pulido, EG | 1 |
| Andrejak, M; Basille, D; Bentayeb, H; Boutemy, M; Dayen, C; Douadi, Y; Fournier, C; Garidi, R; Kanaan, M; Lecuyer, E | 1 |
| Cai, T; Ding, W; He, Q; Lu, W; Tu, C; Wu, R; Yang, B; Yang, L; Zhu, H | 1 |
| Boven, E; Haanen, JB; Meijerink, MR; van den Eertwegh, AJ; van der Veldt, AA | 1 |
| Brown, A; Ginsberg, MS; James, L; Juergens, R; Kris, MG; Krug, LM; Markus, S; Paik, PK; Rizvi, NA; Rudin, CM; Subzwari, S; Takebe, N; Travis, W; Tyson, L | 1 |
| Haseke, N; Stadler, T; Staehler, M; Stief, CG; Zilinberg, K | 1 |
| Cedres, S; Chao, R; Felip, E; Frickhofen, N; Fuhr, HG; Gatzemeier, U; Heigener, D; Lanzalone, S; Reck, M; Ruiz-Garcia, A; Stephenson, P; Thall, A | 1 |
| Austin, B; Ghodousi, A; Hansen, D; Jamil, A; Skibo, EB | 1 |
| Garfield, DH; Hercbergs, A; Schöffski, P; Wolter, P | 1 |
| Bao-Hui, H; Hui-Min, W; Ping, G; Wei-Min, W | 1 |
| Dalhaug, A; Haukland, E; Nieder, C | 1 |
| Kelleher, FC; McDermott, R | 1 |
| Arkadopoulos, N; Gennatas, C; Kondi-Pafiti, A; Michalaki, V | 1 |
| Benesch, M; Hanzer, M; Nebl, A; Pilhatsch, A; Spendel, S; Urban, C | 1 |
| Beck, J; Bellmunt, J; Escudier, B | 1 |
| Ghenev, P; Izumi, K; Kitagawa, S; Mouri, H; Ohtsubo, K; Takeuchi, S; Yamada, T; Yamashita, K; Yano, S; Yasumoto, K | 1 |
| Ghose, A; Tariq, Z; Veltri, S | 1 |
| Fujisawa, M; Haraguchi, T; Miyake, H; Takenaka, A | 1 |
| An, J; Bilenky, M; Birol, I; Butterfield, YS; Cezard, T; Chuah, E; Corbett, R; Fejes, AP; Griffith, M; Griffith, OL; Hirst, M; Holt, RA; Huntsman, DG; Jones, SJ; Laskin, J; Li, YY; Marra, MA; Martin, M; Mayo, M; Melnyk, N; Moore, RA; Morin, RD; Pugh, TJ; Severson, T; Shah, SP; Sutcliffe, M; Tam, A; Terry, J; Thiessen, N; Thomson, T; Varhol, R; Yee, J; Zeng, T; Zhao, Y | 1 |
| Ginsberg, MS; Molina, AM; Motzer, RJ | 1 |
| Canfield, SE; Dahm, P; Sultan, S | 1 |
| Ganser, A; Grünwald, V; Janssen, S; Karstens, JH; Morgan, M; Seidel, C; Welte, T | 1 |
| Altman, J; Kuzel, T; Parajuli, R; Perdekamp, M; Tallman, M | 1 |
| Cecere, FL; Di Costanzo, F; Doni, L; Moscetti, L; Padalino, D; Ruggeri, EM | 1 |
| Andreadis, C; Antonakis, E; Christopoulou, M; Kontovinis, LF; Kortsaris, AH; Kouvatseas, G; Lafaras, C; Mouratidou, D; Papandreou, CN; Papazisis, KT | 1 |
| Chen, LC; Gitlitz, B; Jezior, D; Milne, G; Patel, R; Reckamp, K; Syto, M; Zaknoen, S | 1 |
| Barbaud, A; Cuny, JF; Granel-Brocard, F; Guyot-Caquelin, P; Marchal, A; Schmutz, JL; Spaeth, D; Trechot, P | 1 |
| Balemans, C; Mattijssen, V; Ruinemans, GM; Smit, HJ; Wiersma-van Tilburg, AJ | 1 |
| Chen, YL; Fang, Z; Hua, KF; Lam, Y; Liao, PC; Wu, SH; Yang, FL; Yang, YL | 1 |
| Antón, I; Calvo, A; Catena, R; Larzábal, L; Lecanda, F; Luis-Ravelo, D; Salazar-Colocho, P; Zandueta, C | 1 |
| Abou-Alfa, GK; Bekaii-Saab, T; Douglas, K; Goldberg, RM; Hall, M; Hollis, D; Kindler, HL; Niedzwiecki, D; O'Reilly, EM; Pluard, T; Schilsky, RL | 1 |
| Amundson, K; Baxi, SM; Bender, SL; Bergqvist, S; Buckman, D; Casperson, GF; Chen, E; Chen, JH; Hu-Lowe, DD; Jiang, X; Li, G; Wang, J; Wickman, G; Zhang, L; Zobel, J | 1 |
| Habuchi, T; Horikawa, Y; Narita, S; Numakura, K; Obara, T; Saito, M; Satoh, S; Tsuchiya, N; Tsuruta, H; Yuasa, T | 1 |
| Muto, A; Neri, B; Politi, L; Rangan, S; Tassi, R; Vannini, A | 1 |
| Chen, Z; Jin, H; Lei, Y; Luo, H; Su, C; Wang, T; Zhong, B; Zhuang, M; Zou, J | 1 |
| Beltran, L; Berney, D; Bex, A; Blank, C; Boletti, K; Chowdhury, S; Haanen, J; Horenblas, S; Kayani, I; O'Brien, T; Peters, J; Powles, T; Sadev, A; Sarwar, N; Shamash, J | 1 |
| Rexer, H | 2 |
| Chay, WY; Choong, CV; Goh, C; Tan, MH; Tan, PH; Tang, T; Tay, MH; Zam, NA | 1 |
| Barbry, P; Fromigue, O; Hamidouche, Z; Lecanda, F; Mari, B; Marie, PJ; Patino, A; Vaudin, P | 1 |
| Jiang, Z; Wang, D; Zhang, L | 1 |
| Ayllon, J; Barrascout, E; Beuselinck, B; Medioni, J; Morel, A; Oudard, S; Scotte, F | 1 |
| Berger, M; Blackhall, F; Cummings, J; Dean, EJ; Dive, C; Ranson, M; Roulston, A | 1 |
| Ceresoli, GL; Colombo, P; De Sanctis, R; De Vincenzo, F; Gianoncelli, L; Graziotti, P; Lorenzi, E; Perrino, M; Santoro, A; Simonelli, M; Zucali, PA | 1 |
| Daignault, S; Dy, GK; Gadgeel, SM; Kalemkerian, GP; Ramnath, N; Schneider, BJ; Wozniak, AJ | 1 |
| Bosquée, L; Corhay, JL; Thonnard, AS | 1 |
| Lee, J; Sharma, S; Steele, VE; Zhou, J | 1 |
| Abrey, L; Camps, C; Chao, RC; Grossi, F; Mazieres, J; Novello, S; Patyna, S; Scagliotti, G; Thall, A; Usari, T; Vernejoux, JM; Wang, Z | 1 |
| Brown, A; Ginsberg, MS; James, L; Juergens, R; Kris, MG; Krug, LM; Markus, S; Paik, PK; Pietanza, MC; Rizvi, NA; Rudin, CM; Subzwari, S; Takebe, N; Travis, W; Tyson, L | 1 |
| Gong, P; Lv, Y; Wang, S; Zhang, G; Zhang, N; Zhao, Y | 1 |
| Campbell, TC; Hoang, T; Kim, K; Larson, MM; LoConte, NK; Marcotte, SM; O'Mahar, SE; Seo, S; Traynor, AM | 1 |
| Albain, KS; Besse, B; Blais, N; Chao, RC; Gervais, R; Hainsworth, JD; Hamm, JT; Kim, ST; Laskin, J; Lipton, A; Masters, GA; Natale, RB; Page, RD; Selaru, P | 1 |
| Duprez, O; Gao, F; Paes, MN; Visvardis, EE; Waxman, J | 1 |
| Bernhard, JC; De Clermont, H; Gross-Goupil, M; Quivy, A; Ravaud, A; Roca, S | 1 |
| Kunene, V; Porfiri, E | 1 |
| Ahellal, Y; Errihani, H; Essadi, I; M'rabti, H; Tazi, EM; Tazi, MF | 1 |
| Pan, F; Pan, Y; Tian, J; Zhang, X; Zhang, Y | 1 |
| Filipiak, KJ; Langiewicz, P; Nurzyński, P; Opolski, G; Szczylik, C; Szmit, S; Zaborowska, M; Złnierek, J | 1 |
| Gao, H; Guo, W; Liu, X | 1 |
| Ishihara, A; Kuroda, N; Takamori, H; Yamashita, Y | 1 |
| Chang, PM; Chen, MH; Liu, CY; Liu, YC; Pan, CC; Yang, CY | 1 |
| Blais, N; Camidge, DR; Canil, C; Chao, RC; Chow, LQ; Diab, SG; Jonker, DJ; Laurie, SA; McWilliam, M; Ruiz-Garcia, A; Thall, A; Tye, L; Zhang, K | 1 |
| Chu, Q; Dunlop, D; Hao, D; Jacobs, CD; Leighl, N; Lopez-Anaya, A; Middleton, G; Ramlau, R; Rodon, J; Rowinsky, EK; Takimoto, CH; Wakelee, HA; Zatloukal, P | 1 |
| Díaz de Greñu, B; Espona, M; Iglesias Hernández, P; Light, ME; Pérez-Tomás, R; Quesada, R; Quiñonero, D; Torroba, T | 1 |
| Hokoda, N; Kasahara, K; Kitamura, R; Miyazaki, M; Nakagawa, K; Nakayama, H; Ohyama, A; Okamoto, I; Satouchi, M; Seto, T; Takeda, K; Yamamoto, N; Yoshihara, E; Yoshioka, H | 1 |
| Drabkin, HA; Gemmill, RM; Lay, A; Lee, L; Lloyd, GK; Longenecker, A; McConkey, DJ; Millward, M; Neuteboom, ST; Palladino, MA; Price, T; Sharma, G; Spear, MA; Spencer, A; Sukumaran, S; Sweeney, C; Townsend, A | 1 |
| An, Y; Chen, J; Li, X; Liu, B; Pan, Y; Tie, L; Yang, J; Yuan, J; Zhang, J | 1 |
| Casto, BC; Knobloch, TJ; Lubet, RA; Pereira, MA; Steele, VE; Warner, BM; Weghorst, CM | 1 |
| Brisse, H; Coulomb, A; Helfre, S; Hilbert, M; Larroquet, M; Mary, P; Orbach, D; Serinet, MO | 1 |
| Christensen, JG; Lappin, PB; Lee, JH; Shojaei, F; Simmons, BH | 1 |
| An, Y; Chen, J; Hou, J; Lan, T; Li, X; Liu, J; Pan, Y; Tie, L; Zhang, J | 1 |
| Berger, MS; Blakely, J; Chiappori, AA; Chu, QS; Moezi, MM; Ross, HJ; Salgia, R; Schnyder, J; Schreeder, MT; Stephenson, JJ; Subramaniam, DS | 1 |
| Schmuck, K; Sieber, SA; Tietze, LF; Wirth, T | 1 |
| Kang, WK; Lee, J; Lim, HY; Park, JO; Park, SH; Park, YS; Yi, JH; Yim, DS | 1 |
| An, Y; Chen, J; Hou, J; Li, X; Liu, J; Yue, L; Zhang, J; Zhang, X | 1 |
| Burris, HA; Eakle, JF; Greco, FA; Hainsworth, JD; Lubiner, ET; Quinn, R; Rubin, MS; Shipley, D; Spigel, DR; Thompson, DS | 1 |
| Albert, I; Chao, RC; Govindan, R; Karaseva, N; Krzakowski, M; Makhson, A; Miziara, JE; Papai, ZS; Portulas, ED; Reck, M; Scagliotti, GV; Selaru, P; Strausz, J; Szczesna, A; Thomas, M; Thongprasert, S; Tye, L; von Pawel, J; Wierzbicki, RF; Zhang, K | 1 |
| Ikeda, A; Iwasaki, H; Kawai, K; Kimura, T; Kojima, T; Miyazaki, J; Nishiyama, H; Oikawa, T; Shimano, H; Suetomi, T; Takaoka, E; Yoshino, T | 1 |
| Barck, KH; Cao, TC; Carano, RA; Cheng, JH; Couto, SS; Eastham-Anderson, J; Ferrara, N; Foreman, O; Forrest, WF; Hamilton, P; Ho, CC; Johnson, L; Jubb, AM; Kasman, I; Lima, A; Long, JE; McNutt, A; Molina, R; Nannini, MA; Reslan, HB; Singh, M | 1 |
| Aide, N; Bardet, S; Crouzeix, G; Michels, JJ; Sevin, E; Vaur, D | 1 |
| Blumenschein, GR; Chao, RC; Ciuleanu, T; Groen, HJ; Juhasz, E; Robert, F; Ruiz-Garcia, A; Tye, L; Usari, T | 1 |
| Arbour, N; Forget, MA; Grange, C; Huon, Y; Lapointe, R; Liberman, M; Martin, J; Mes-Masson, AM; Reuben, A | 1 |
| Anderson, J; Bier, N; Cherian, A; Chowdhury, T; O'Meara, A; Prichard-Jones, K; Sebire, NJ; Sullivan, MO | 1 |
| Aguilar, A; Bai, L; Chen, J; Liu, L; McEachern, D; Meagher, JL; Stuckey, JA; Wang, S; Yang, CY; Zhou, H | 1 |
| Abbas, M; Herrmann, TR; Jüttner, B; Kramer, M; Kuczyk, MA; Merseburger, AS; Peters, I; Reichelt, A; Teebken, OE; von Klot, C; Winkler, M | 1 |
| Blais, N; Camidge, DR; Chao, RC; Chow, LQ; Doebele, RC; Jonker, DJ; Laurie, SA; Ruiz-Garcia, A; Soulières, D; Thall, A; Zhang, K | 1 |
| Ali, MM; El Diwani, HI; Galal, SA; Kerwin, SM; Li, J; Omar, MA; Ramadan, RA; Shaker, YM; Tokuda, H | 1 |
| Han, JH; Han, JY; Kim, HJ; Kim, HT; Kim, HY; Kwak, MH; Lee, JS; Lee, YJ; Lim, KY; Yun, T | 1 |
| Kummer, G; Schultheis, B; Strumberg, D | 1 |
| Huang, J; Huang, Y; Wang, T | 1 |
| Corso, G; Di Mare, G; Lambert, Y; Marrelli, D; Mastrogiacomo, D; Neri, A; Roviello, F; Volterrani, L | 1 |
| Baselga, J; Hammond, LA | 1 |
| Curran, WJ | 1 |
| Bajo, AM; Halmos, G; Hebert, F; Nagy, A; Schally, AV; Szepeshazi, K; Szereday, Z | 1 |
| Abrams, TJ; Cherrington, JM; Lee, LB; Murray, LJ; Pryer, NK | 1 |
| Bonomi, P | 1 |
| Cao, C; Choy, H; Freeman, ML; Morrow, JD; Saha, D; Sekhar, KR | 1 |
| Broggini, M; Colombo, T; Geroni, C; Marchini, S; Sabatino, MA | 1 |
| Abdollahi, A; Bischof, M; Debus, J; Grone, HJ; Hahnfeldt, P; Han, X; Hlatky, L; Huber, PE; Klenke, F; Krix, M; Lipson, KE; Poerschke, D; Roth, A; Sckell, A; Zieher, H | 1 |
| Kobayashi, K | 1 |
| Krystal, GW; Lipson, KE; Litz, J; Sakuntala Warshamana-Greene, G; Sulanke, G | 1 |
| Fidler, IJ; Herbst, RS; Isobe, T; Itasaka, S; Kenji, Y; O'reilly, MS; Onn, A; Shibuya, K; Shintani, T; Wu, W | 1 |
| Buchdunger, E; García-Echeverría, C; Hofmann, F; Krystal, GW; Litz, J; Warshamana-Greene, GS | 1 |
| Fu, M; Guo, S; Li, S; Liang, X; Lin, C; Lu, H; Wu, M; Zhang, X; Zheng, Z | 1 |
| Donnelly, EF; Fleischer, AC; Geng, L; Hallahan, DE; Niermann, KJ; Schueneman, AJ | 1 |
| Ganti, AK; Potti, A | 1 |
| Schiller, JH; Wakelee, HA | 1 |
| Marian, B; Nohl, H; Rohr-Udilova, N; Stolze, K | 1 |
| Ardizzoni, A; Franciosi, V; Tiseo, M | 1 |
| Buhaescu, I; Deray, G; Izzedine, H; Rixe, O | 1 |
| Herbst, RS | 1 |
| Cuneo, KC; Fu, A; Geng, L; Osusky, KL | 1 |
| Colantuoni, G; Comunale, D; De Vita, A; Del Gaizo, F; Ferrara, C; Gridelli, C; Guerriero, C; Maione, P; Nicolella, D; Rossi, A | 1 |
| Bringmann, G; Krewer, B; Magull, J; Major, F; Maksimenka, K; Schuberth, I; Spiegl, DA; Tietze, LF | 1 |
| Ardizzoni, A; Tiseo, M | 1 |
| De Mulder, PH; Mulder, SF; van Spronsen, DJ | 1 |
| Haura, EB; Li, J; Viallet, J | 1 |
| Bargetzi, M; Puric, E; Schönenberger, A; Sendi, P | 1 |
| Cabebe, E; Wakelee, H | 1 |
| Belcaceres, JL; Cojocarasu, O; Halimi, P; Medioni, J; Oudard, S | 1 |
| Scagliotti, GV | 1 |
| Adams, VR; Leggas, M | 1 |
| Alba, E; Medina, MA; Quesada, AR | 1 |
| Polyzos, A | 1 |
| Belt, RJ; Bergsland, EK; Chao, RC; Chow-Maneval, E; DePrimo, SE; Eckhardt, SG; Haller, DG; Huang, X; Hurwitz, HI; Lenz, HJ; Lockhart, AC; Marshall, JL; Rocha Lima, CM; Rosen, LS; Saltz, LB | 1 |
| Bhide, RS; Borzilleri, RM; Cai, ZW; Fargnoli, J; Henley, BJ; Hunt, JT; Jeyaseelan, R; Kamath, A; Lombardo, LJ; Mortillo, S; Qian, L; Tokarski, J; Wautlet, B; Wei, D | 1 |
| Kidd, M; Malfertheiner, MV; Modlin, IM; Pfragner, R; Schally, AV | 1 |
| Atkins, JN; Belani, CP; Brahmer, JR; Chao, RC; Gillenwater, HH; Govindan, R; Novello, S; Pallares, C; Rosell, R; Sanchez, JM; Scagliotti, GV; Selaru, P; Socinski, MA; Tye, L | 1 |
| Bukowski, RM; Garcia, J; Heng, DY; Rini, BI; Wood, L | 1 |
| Bletard, N; Bonbled, F; Duck, L; Jacquet, L; Machiels, JP; Pirenne, P | 1 |
| Dudek, AZ; Mulamalla, K; Truskinovsky, AM | 1 |
| Barbosa, S; Barrish, JC; Bhide, RS; Borzilleri, RM; Cai, ZW; D'Arienzo, C; Derbin, G; Fan, J; Fargnoli, J; Hunt, JT; Jeyaseelan, R; Kamath, A; Kukral, DW; Lombardo, LJ; Marathe, P; Mortillo, S; Qian, L; Robl, JA; Shi, Z; Wautlet, BS; Wei, D; Wu, L; Zhang, Y; Zheng, X | 1 |
| Abbruzzese, JL; Chiao, PJ; Fleming, JB; Ishiyama, S; Melisi, D; Sclabas, GM; Tortora, G; Xia, Q | 1 |
| Buhl, R; Fischer, B | 1 |
| Anderson, WK | 1 |
| Ewy, GA | 1 |
| Asai, A; Ashizawa, T; Kakita, S; Mihara, A; Mizukami, T; Nakano, H; Ochiai, K; Ogawa, H; Sakai, Y; Yamashita, Y | 1 |
| Carter, SK | 1 |
| Halmos, G; Hebert, F; Kiaris, H; Nagy, A; Plonowski, A; Schally, AV | 1 |
| Halmos, G; Hebert, F; Kiaris, H; Nagy, A; Schally, AV; Szepeshazi, K | 1 |
| Honsawek, S; Kiewlich, D; Krystal, GW; Liang, C; Lipson, KE; McMahon, G; Sun, L; Vasile, S | 1 |
| Beauchamp, RD; Choy, H; Johnson, D; Nanney, L; Parman, K; Riordan, C; Roman, CD | 1 |
| Cabral, JR; Mattocks, AR | 1 |
| Akimoto, H; Hitaka, T; Miwa, T; Nomura, H | 1 |
31 review(s) available for pyrroles and Lung Neoplasms
| Article | Year |
|---|---|
Advances in Treatment of Recurrent Small Cell Lung Cancer (SCLC): Insights for Optimizing Patient Outcomes from an Expert Roundtable Discussion.
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Pyrimidines; Pyrroles; Small Cell Lung Carcinoma | 2021 |
Pyrrole-based EGFR inhibitors for the treatment of NCSLC: Binding modes and SARs investigations.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Pyrroles | 2023 |
Conducting polymer composite-based biosensing materials for the diagnosis of lung cancer: A review.
Topics: Biomarkers; Biosensing Techniques; Electrochemical Techniques; Humans; Lung Neoplasms; Molecularly Imprinted Polymers; Polymers; Pyrroles | 2023 |
Angiogenesis Inhibitors in NSCLC.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Disease-Free Survival; Docetaxel; Humans; Indoles; Lung Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Piperidines; Pyrroles; Quinazolines; Ramucirumab; Sorafenib; Sunitinib; Taxoids | 2017 |
Efficacy and safety of angiogenesis inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Hemorrhage; Humans; Indazoles; Indoles; Lung Neoplasms; Niacinamide; Odds Ratio; Phenylurea Compounds; Piperidines; Pyrimidines; Pyrroles; Quinazolines; Ramucirumab; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib; Sulfonamides; Sunitinib; Thrombocytopenia; Treatment Outcome; Vascular Endothelial Growth Factor A | 2015 |
Topics: AC133 Antigen; Acenaphthenes; Acer; Acrosome Reaction; Adult; Agaricales; Aged; Aged, 80 and over; Animals; Animals, Zoo; Anti-Bacterial Agents; Anticoagulants; Antifungal Agents; Antimanic Agents; Antioxidants; Aortic Valve; Area Under Curve; ATP Binding Cassette Transporter, Subfamily G, Member 2; Bacillus; Bacterial Toxins; Bacterial Typing Techniques; Base Composition; Beauveria; Binge Drinking; Biomarkers; Bipolar Disorder; Blood Coagulation; Blotting, Western; Brachytherapy; Calcium Channels, L-Type; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Cell Wall; Cells, Cultured; Ceramics; Chi-Square Distribution; China; Chlorophyll; Chlorophyta; Chloroplasts; Cholesterol, HDL; Chromatography, High Pressure Liquid; Chromobacterium; Clostridium perfringens; Clozapine; Constriction, Pathologic; Coronary Artery Bypass; Corticotropin-Releasing Hormone; Cross-Sectional Studies; Cytochrome P-450 CYP2C9; Dental Porcelain; Dental Restoration Failure; Dental Stress Analysis; Designer Drugs; Diaminopimelic Acid; DNA Fingerprinting; DNA, Bacterial; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Drug Dosage Calculations; Drug Evaluation, Preclinical; Drug Resistance, Bacterial; Elasticity Imaging Techniques; Epsilonproteobacteria; Equipment Design; Ericaceae; Excitatory Amino Acid Antagonists; False Negative Reactions; Fatty Acids; Female; Food Analysis; Fresh Water; Gene Expression Regulation, Neoplastic; Glutathione; Graft Occlusion, Vascular; Heart Valve Prosthesis Implantation; Heart Ventricles; HEK293 Cells; Hemolymph; Humans; Hyaluronan Receptors; Hydrogen Peroxide; Hydrothermal Vents; Indoles; Inflammation Mediators; Inhibitory Concentration 50; Insecta; International Normalized Ratio; Isotope Labeling; Itraconazole; Kidney; Kinetics; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Lamotrigine; Lanthanoid Series Elements; Limit of Detection; Linear Models; Lipid Peroxidation; Liver; Liver Cirrhosis; Logistic Models; Lung Neoplasms; Lymph Node Excision; Lymphatic Metastasis; Male; Malondialdehyde; Mediastinum; Metronidazole; Mice; Mice, Nude; Mice, Transgenic; Microbial Sensitivity Tests; Microscopy, Fluorescence; Middle Aged; Monocytes; Monomeric GTP-Binding Proteins; Multivariate Analysis; Myocytes, Cardiac; Neoplasm Staging; Neoplastic Stem Cells; Neural Pathways; Nitrates; Nucleic Acid Hybridization; Octamer Transcription Factor-3; Odds Ratio; Oxidation-Reduction; Oxidative Stress; Peptidoglycan; Phantoms, Imaging; Pharmacogenetics; Pharmacogenomic Variants; Phenotype; Phospholipids; Photolysis; Photosynthesis; Phylogeny; Plant Extracts; Polychaeta; Polymerase Chain Reaction; Polymorphism, Single Nucleotide; Positron Emission Tomography Computed Tomography; Predictive Value of Tests; Preoperative Care; Prostatic Neoplasms; Pseudomonas aeruginosa; Pyrimidines; Pyrroles; Quorum Sensing; Radiology, Interventional; Radiopharmaceuticals; Radiotherapy Dosage; Rats; Rats, Sprague-Dawley; Receptors, Corticotropin-Releasing Hormone; Reference Values; Regression Analysis; Retrospective Studies; Reverse Transcriptase Polymerase Chain Reaction; Rhizosphere; Risk Factors; RNA, Ribosomal, 16S; ROC Curve; Rutin; Saphenous Vein; Seawater; Selenium; Semen Preservation; Sensitivity and Specificity; Septal Nuclei; Sequence Analysis, DNA; Serum Albumin; Serum Albumin, Human; Shear Strength; Sodium Pertechnetate Tc 99m; Sodium-Hydrogen Exchangers; Soil Microbiology; SOXB1 Transcription Factors; Spain; Species Specificity; Sperm Motility; Spermatozoa; Spheroids, Cellular; Spores, Fungal; Stroke; Superoxide Dismutase; Swine; Tandem Mass Spectrometry; Technetium Compounds; Technetium Tc 99m Exametazime; Technetium Tc 99m Sestamibi; Temperature; Thiosulfates; Thrombosis; Thyroid Neoplasms; Transducers; Transfection; Transplantation, Heterologous; Treatment Outcome; Triazines; Tumor Burden; Urocortins; Uterine Cervical Neoplasms; Vacuoles; Valproic Acid; Ventral Tegmental Area; Vitamin K 2; Vitamin K Epoxide Reductases; Warfarin; Water Microbiology; Young Adult | 2016 |
[Metastasis to the Tongue from Renal Cell Carcinoma 10 Years after Nephrectomy : A Case Report].
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Lung Neoplasms; Nephrectomy; Pyrroles; Recurrence; Remission Induction; Sunitinib; Tomography, X-Ray Computed; Tongue Neoplasms | 2016 |
Benefit of Sunitinib in the treatment of pulmonary primitive neuroectodermal tumors: a case report and literature review.
Topics: Adult; Antineoplastic Agents; DNA Copy Number Variations; Female; Humans; Indoles; Lung Neoplasms; Neuroectodermal Tumors, Primitive; Pyrroles; Sunitinib; Tomography, X-Ray Computed; Von Hippel-Lindau Tumor Suppressor Protein | 2016 |
Visceral and bone metastases of a WHO grade 2 meningioma: A case report and review of the literature.
Topics: Adult; Antineoplastic Agents; Bone Neoplasms; Combined Modality Therapy; Female; Humans; Ilium; Indoles; Liver Neoplasms; Lung Neoplasms; Magnetic Resonance Imaging; Meningeal Neoplasms; Meningioma; Neoplasm Grading; Pyrroles; Radiotherapy, Adjuvant; Radiotherapy, Intensity-Modulated; Ribs; Spinal Cord Compression; Spinal Neoplasms; Spine; Sunitinib | 2017 |
Targeted therapy in advanced non-small-cell lung cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Drug Delivery Systems; Epidermal Growth Factor; Erlotinib Hydrochloride; Humans; Indoles; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Signal Transduction; Sorafenib; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor A | 2008 |
The current status and evolving role of sunitinib in non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Indoles; Lung Neoplasms; Male; Maximum Tolerated Dose; Neoplasm Staging; Prognosis; Pyrroles; Risk Assessment; Sunitinib; Survival Analysis; Treatment Outcome | 2008 |
Emerging data with antiangiogenic therapies in early and advanced non-small-cell lung cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Humans; Indoles; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; Thalidomide; Vascular Endothelial Growth Factor A | 2009 |
Targeted therapies in the treatment of advanced/metastatic NSCLC.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cetuximab; Erlotinib Hydrochloride; Gefitinib; Humans; Indoles; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Piperidines; Pyridines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Treatment Outcome | 2009 |
Recovery of paraneoplastic hypercalcemia by sunitinib treatment for renal cell carcinoma: a case report and review of the literature.
Topics: Adult; Antineoplastic Agents; Carcinoma, Renal Cell; Combined Modality Therapy; Disease Progression; Humans; Hypercalcemia; Indoles; Kidney Neoplasms; Lung Neoplasms; Male; Nephrectomy; Paraneoplastic Syndromes; Pneumonectomy; Protein Kinase Inhibitors; Pyrroles; Sunitinib | 2010 |
Understanding the molecular-based mechanism of action of the tyrosine kinase inhibitor: sunitinib.
Topics: Angiogenesis Inhibitors; Breast Neoplasms; Carcinoma, Renal Cell; Colonic Neoplasms; Drug Resistance, Neoplasm; Female; Gastrointestinal Stromal Tumors; Humans; Indoles; Lung Neoplasms; Neovascularization, Pathologic; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Sunitinib | 2010 |
The emerging pathogenic and therapeutic importance of the anaplastic lymphoma kinase gene.
Topics: Anaplastic Lymphoma Kinase; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chromosome Aberrations; Chromosomes, Human, Pair 2; Drug Synergism; Gene Amplification; Humans; Lung Neoplasms; Lymphoma, Large-Cell, Anaplastic; Mutation; Neoplasms; Neuroblastoma; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Receptor Protein-Tyrosine Kinases; Receptor, IGF Type 1 | 2010 |
HER-targeted tyrosine-kinase inhibitors.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Head and Neck Neoplasms; Humans; Lung Neoplasms; Morpholines; Ovarian Neoplasms; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Quinazolines; Receptor, ErbB-2 | 2002 |
New chemotherapeutic agents: update of major chemoradiation trials in solid tumors.
Topics: Alkyl and Aryl Transferases; Angiogenesis Inhibitors; Angiostatins; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dose Fractionation, Radiation; Drugs, Investigational; Endothelial Growth Factors; Enzyme Inhibitors; Esophageal Neoplasms; Farnesyltranstransferase; Female; Head and Neck Neoplasms; Humans; Indoles; Intercellular Signaling Peptides and Proteins; Isoenzymes; Laryngeal Neoplasms; Lung Neoplasms; Lymphokines; Male; Membrane Proteins; Neoplasms; Peptide Fragments; Plasminogen; Prostaglandin-Endoperoxide Synthases; Prostatic Neoplasms; Pyrroles; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Treatment Outcome; Uterine Cervical Neoplasms; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2002 |
Clinical studies with non-iressa EGFR tyrosine kinase inhibitors.
Topics: Aminoquinolines; Aniline Compounds; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lapatinib; Lung Neoplasms; Organic Chemicals; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Quinazolines; Treatment Outcome | 2003 |
[Lung cancer: molecular targeting therapy].
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Gene Targeting; Genetic Therapy; Humans; Imatinib Mesylate; Indoles; Lung Neoplasms; Piperazines; Pyrimidines; Pyrroles; Quinazolines; Receptor Protein-Tyrosine Kinases; Signal Transduction; Trastuzumab | 2004 |
Early clinical data with small-molecule vascular endothelial growth factor tyrosine kinase receptor inhibitors.
Topics: Angiogenesis Inhibitors; Clinical Trials, Phase I as Topic; Female; Humans; Indoles; Lung Neoplasms; Male; Neoplasm Invasiveness; Neovascularization, Pathologic; Phthalazines; Prognosis; Pyridines; Pyrroles; Receptor Protein-Tyrosine Kinases; Receptors, Vascular Endothelial Growth Factor; Risk Assessment; Sunitinib; Treatment Outcome | 2004 |
Epidermal growth factor inhibition in solid tumours.
Topics: Administration, Oral; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; Colorectal Neoplasms; Drug Delivery Systems; Drug Evaluation, Preclinical; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Panitumumab; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Quinazolines; Randomized Controlled Trials as Topic | 2005 |
Targeting angiogenesis with vascular endothelial growth factor receptor small-molecule inhibitors: novel agents with potential in lung cancer.
Topics: Benzenesulfonates; Clinical Trials as Topic; Humans; Indoles; Lung Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Phthalazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2005 |
Multi-target inhibitors in non-small cell lung cancer (NSCLC).
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Indoles; Lung Neoplasms; Medical Oncology; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Sorafenib; Sunitinib | 2006 |
Toxicities of antiangiogenic therapy in non-small-cell lung cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Humans; Indoles; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Piperidines; Pyridines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Vascular Endothelial Growth Factors | 2006 |
Combination of target agents: challenges and opportunities.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Drug Resistance, Neoplasm; Humans; Indoles; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Piperidines; Pyridines; Pyrroles; Quinazolines; Receptor Protein-Tyrosine Kinases; Sorafenib; Sunitinib | 2007 |
Role of anti-angiogenesis agents in treating NSCLC: focus on bevacizumab and VEGFR tyrosine kinase inhibitors.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Enzyme Inhibitors; Humans; Indoles; Lung Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Piperidines; Pyridines; Pyrroles; Quinazolines; Signal Transduction; Sorafenib; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-1 | 2007 |
Sunitinib malate for the treatment of metastatic renal cell carcinoma and gastrointestinal stromal tumors.
Topics: Age Factors; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Female; Gastrointestinal Stromal Tumors; Humans; Indoles; Kidney Neoplasms; Lactation; Lung Neoplasms; Neuroendocrine Tumors; Pregnancy; Pyrroles; Receptor Protein-Tyrosine Kinases; Sunitinib | 2007 |
Playing only one instrument may be not enough: limitations and future of the antiangiogenic treatment of cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Indoles; Lung Neoplasms; Models, Biological; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2007 |
Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma and various other solid tumors.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Renal Cell; Female; Gastrointestinal Stromal Tumors; Humans; Indoles; Kidney Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neuroendocrine Tumors; Pyrroles; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Sunitinib | 2008 |
[Lung cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Combined Modality Therapy; Drugs, Investigational; Erlotinib Hydrochloride; Humans; Indoles; Lung Neoplasms; Mass Screening; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Piperidines; Pneumonectomy; Pyridines; Pyrroles; Quinazolines; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Sorafenib; Sunitinib | 2008 |
63 trial(s) available for pyrroles and Lung Neoplasms
| Article | Year |
|---|---|
Trilaciclib and the economic value of multilineage myeloprotection from chemotherapy-induced myelosuppression among patients with extensive-stage small cell lung cancer treated with first-line chemotherapy.
Topics: Antineoplastic Agents; Humans; Lung Neoplasms; Pyrimidines; Pyrroles; Quality of Life; Small Cell Lung Carcinoma | 2021 |
FIGHT-101, a first-in-human study of potent and selective FGFR 1-3 inhibitor pemigatinib in pan-cancer patients with FGF/FGFR alterations and advanced malignancies.
Topics: Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Carcinoma, Non-Small-Cell Lung; Carcinoma, Transitional Cell; Cholangiocarcinoma; Female; Fibroblast Growth Factors; Humans; Lung Neoplasms; Male; Morpholines; Neoplasm Recurrence, Local; Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Receptors, Fibroblast Growth Factor; Urinary Bladder Neoplasms | 2022 |
Phase 1b trial of anti-VEGF/PDGFR vorolanib combined with immune checkpoint inhibitors in patients with advanced solid tumors.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Humans; Immune Checkpoint Inhibitors; Indoles; Lung Neoplasms; Neoplasms; Nivolumab; Pyrroles; Pyrrolidines | 2022 |
Pharmacokinetic Drug-Drug Interaction Studies Between Trilaciclib and Midazolam, Metformin, Rifampin, Itraconazole, and Topotecan in Healthy Volunteers and Patients with Extensive-Stage Small-Cell Lung Cancer.
Topics: Area Under Curve; Drug Interactions; Healthy Volunteers; Humans; Itraconazole; Lung Neoplasms; Metformin; Midazolam; Prospective Studies; Pyrimidines; Pyrroles; Rifampin; Topotecan | 2022 |
Fibroblast growth factor receptor (FGFR) inhibitor rogaratinib in patients with advanced pretreated squamous-cell non-small cell lung cancer over-expressing FGFR mRNA: The SAKK 19/18 phase II study.
Topics: Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Humans; Lung Neoplasms; Piperazines; Protein Kinase Inhibitors; Pyrroles; RNA, Messenger; Thiophenes | 2022 |
Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL Surveillance trial.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Lung Neoplasms; Pyrroles; Risk Factors; Skin Neoplasms; Treatment Outcome; Tumor Necrosis Factor Inhibitors | 2023 |
Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study.
Topics: Acute Kidney Injury; Aged; Anorexia; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Transitional Cell; Diarrhea; Fatigue; Female; Humans; Hyperphosphatemia; Hypoglycemia; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Piperazines; Pyrroles; Receptor, Fibroblast Growth Factor, Type 1; Receptor, Fibroblast Growth Factor, Type 2; Receptor, Fibroblast Growth Factor, Type 3; Receptors, Fibroblast Growth Factor; RNA, Messenger; Squamous Cell Carcinoma of Head and Neck; Thiophenes; Vomiting | 2019 |
Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Cisplatin; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Double-Blind Method; Etoposide; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Myeloid Cells; Paclitaxel; Prognosis; Pyrimidines; Pyrroles; Small Cell Lung Carcinoma; Survival Rate; Tissue Distribution | 2019 |
Single-center study to determine the safety and efficacy of CT-707 in Chinese patients with advanced anaplastic lymphoma kinase-rearranged non-small-cell lung cancer.
Topics: Adenocarcinoma of Lung; Adolescent; Adult; Aged; Anaplastic Lymphoma Kinase; Female; Follow-Up Studies; Gene Rearrangement; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Mesothelioma, Malignant; Middle Aged; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Sulfonamides; Survival Rate; Young Adult | 2020 |
Exploratory composite endpoint demonstrates benefit of trilaciclib across multiple clinically meaningful components of myeloprotection in patients with small cell lung cancer.
Topics: Aged; Cytoprotection; Double-Blind Method; Female; Follow-Up Studies; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Myeloid Cells; Prognosis; Prospective Studies; Pyrimidines; Pyrroles; Small Cell Lung Carcinoma | 2021 |
Trilaciclib prior to chemotherapy reduces the usage of supportive care interventions for chemotherapy-induced myelosuppression in patients with small cell lung cancer: Pooled analysis of three randomized phase 2 trials.
Topics: Antineoplastic Agents; Double-Blind Method; Female; Humans; Lung Neoplasms; Male; Neutropenia; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Retrospective Studies; Small Cell Lung Carcinoma | 2021 |
Phase I-IIa study of BMS-690514, an EGFR, HER-2 and -4 and VEGFR-1 to -3 oral tyrosine kinase inhibitor, in patients with advanced or metastatic solid tumours.
Topics: Administration, Oral; Adult; Aged; Area Under Curve; Carcinoma, Non-Small-Cell Lung; Diarrhea; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Humans; Lung Neoplasms; Male; Metabolic Clearance Rate; Middle Aged; Neoplasm Metastasis; Neoplasms; Piperidines; Protein Kinase Inhibitors; Pyrroles; Quinazolines; Receptor, ErbB-2; Treatment Outcome; Triazines; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-3 | 2013 |
A phase I trial of sunitinib and rapamycin in patients with advanced non-small cell lung cancer.
Topics: Administration, Oral; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Diarrhea; Drug Administration Schedule; Female; Humans; Indoles; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pyrroles; Sirolimus; Sunitinib; Treatment Outcome | 2013 |
Sunitinib malate in previously untreated, nonsquamous, non-small cell lung cancer patients over the age of 70 years: results of a Phase II trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Humans; Indoles; Lung Neoplasms; Male; Protein Kinase Inhibitors; Pyrroles; Quality of Life; Sunitinib; Treatment Outcome | 2013 |
A randomized, double-blind, phase II study of erlotinib with or without sunitinib for the second-line treatment of metastatic non-small-cell lung cancer (NSCLC).
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Double-Blind Method; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Indoles; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Pyrroles; Quinazolines; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Sunitinib; Survival; Treatment Outcome | 2013 |
Sunitinib combined with pemetrexed and carboplatin in patients with advanced solid malignancies--results of a phase I dose-escalation study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Female; Glutamates; Guanine; Humans; Indoles; Leukopenia; Lung Neoplasms; Male; Maximum Tolerated Dose; Mesothelioma; Middle Aged; Pemetrexed; Pyrroles; Sunitinib; Young Adult | 2013 |
Obatoclax mesylate, a pan-bcl-2 inhibitor, in combination with docetaxel in a phase 1/2 trial in relapsed non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Indoles; Lung Neoplasms; Maximum Tolerated Dose; Neoplasm Recurrence, Local; Pyrroles; Taxoids | 2014 |
CALGB 30704 (Alliance): A randomized phase II study to assess the efficacy of pemetrexed or sunitinib or pemetrexed plus sunitinib in the second-line treatment of advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Female; Follow-Up Studies; Glutamates; Guanine; Humans; Indoles; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pemetrexed; Prognosis; Pyrroles; Remission Induction; Salvage Therapy; Sunitinib; Survival Rate | 2014 |
A randomized, placebo-controlled, multicenter, biomarker-selected, phase 2 study of apricoxib in combination with erlotinib in patients with advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cyclooxygenase 2 Inhibitors; Disease Progression; Double-Blind Method; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Prospective Studies; Prostaglandins; Protein Kinase Inhibitors; Pyrroles; Quinazolines; Sulfonamides; Survival Rate | 2014 |
Randomized phase II study of carboplatin and etoposide with or without obatoclax mesylate in extensive-stage small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Comorbidity; Etoposide; Female; Humans; Indoles; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Pyrroles; Small Cell Lung Carcinoma; Treatment Outcome | 2014 |
Randomized, double-blind, placebo-controlled, multicenter phase II study of the efficacy and safety of apricoxib in combination with either docetaxel or pemetrexed in patients with biomarker-selected non-small-cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cyclooxygenase 2; Disease-Free Survival; Docetaxel; Double-Blind Method; Drug Administration Schedule; Female; Glutamates; Guanine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Patient Selection; Pemetrexed; Prostaglandins; Pyrroles; Sulfonamides; Taxoids; Treatment Outcome | 2015 |
Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trial.
Topics: Adolescent; Adult; Aged; Benzimidazoles; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Class I Phosphatidylinositol 3-Kinases; ErbB Receptors; Erlotinib Hydrochloride; Female; Genes, ras; Humans; Indoles; Lapatinib; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Mutation; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; PTEN Phosphohydrolase; Pyrroles; Quinazolines; ras Proteins; Reproducibility of Results; Small Cell Lung Carcinoma; Sunitinib; Thymus Neoplasms; Treatment Outcome; Young Adult | 2015 |
Chemotherapy With or Without Maintenance Sunitinib for Untreated Extensive-Stage Small-Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase II Study-CALGB 30504 (Alliance).
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Disease Progression; Disease-Free Survival; Double-Blind Method; Etoposide; Female; Humans; Indoles; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Proportional Hazards Models; Pyrroles; Small Cell Lung Carcinoma; Sunitinib; Treatment Outcome | 2015 |
SWITCH: A Randomised, Sequential, Open-label Study to Evaluate the Efficacy and Safety of Sorafenib-sunitinib Versus Sunitinib-sorafenib in the Treatment of Metastatic Renal Cell Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Lymph Nodes; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Pyrroles; Sorafenib; Sunitinib | 2015 |
Combined radiation therapy and sunitinib for preoperative treatment of soft tissue sarcoma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Chemoradiotherapy; Extremities; Female; Follow-Up Studies; Humans; Indoles; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Preoperative Care; Prognosis; Prospective Studies; Pyrroles; Radiotherapy, Adjuvant; Retroperitoneal Neoplasms; Sarcoma; Sunitinib | 2015 |
The National Lung Matrix Trial: translating the biology of stratification in advanced non-small-cell lung cancer.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Proto-Oncogene Proteins c-akt; Pyrimidines; Pyrroles; Translational Research, Biomedical; United Kingdom | 2015 |
Phase 2 clinical trial of sunitinib as adjunctive treatment in patients with advanced differentiated thyroid cancer.
Topics: Adenocarcinoma, Follicular; Adenoma, Oxyphilic; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Neoplasms; Carcinoma; Carcinoma, Papillary; Chemotherapy, Adjuvant; Diarrhea; Disease-Free Survival; Fatigue; Female; Hand-Foot Syndrome; Humans; Indoles; Iodine Radioisotopes; Leukopenia; Lung Neoplasms; Male; Middle Aged; Nausea; Pyrroles; Radiotherapy; Sunitinib; Thyroid Cancer, Papillary; Thyroid Neoplasms | 2016 |
Sunitinib (SU11248) in patients with chemo naive extensive small cell lung cancer or who have a 'chemosensitive' relapse: A single-arm phase II study (EORTC-08061).
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Disease Progression; Drug Administration Schedule; Early Termination of Clinical Trials; Female; Humans; Indoles; Lung Neoplasms; Male; Middle Aged; Multimodal Imaging; Neoplasm Recurrence, Local; Patient Selection; Positron-Emission Tomography; Predictive Value of Tests; Protein Kinase Inhibitors; Pyrroles; Sample Size; Small Cell Lung Carcinoma; Sunitinib; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2016 |
Evaluation of Safety and Efficacy of Salvage Therapy With Sunitinib, Docetaxel (Tyxan) and Cisplatinum Followed by Maintenance Vinorelbine for Unresectable/Metastatic Nonsmall Cell Lung Cancer: Stage 1 of a Simon 2 Stage Clinical Trial. [Corrected].
Topics: Adult; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Female; Humans; Indoles; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Pyrroles; Salvage Therapy; Sunitinib; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2015 |
Positive Interaction between Prophylactic Cranial Irradiation and Maintenance Sunitinib for Untreated Extensive-Stage Small Cell Lung Cancer Patients After Standard Chemotherapy: A Secondary Analysis of CALGB 30504 (ALLIANCE).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Cranial Irradiation; Disease-Free Survival; Etoposide; Female; Humans; Indoles; Lung Neoplasms; Maintenance Chemotherapy; Male; Middle Aged; Placebos; Pyrroles; Retrospective Studies; Small Cell Lung Carcinoma; Sunitinib | 2016 |
Maintenance Sunitinib following Initial Platinum-Based Combination Chemotherapy in Advanced-Stage IIIB/IV Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study-CALGB 30607 (Alliance).
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Double-Blind Method; Drug Eruptions; Fatigue; Female; Humans; Hypertension; Indoles; Intention to Treat Analysis; Lung Neoplasms; Maintenance Chemotherapy; Male; Middle Aged; Mucositis; Neoplasm Staging; Neutropenia; Platinum Compounds; Pyrroles; Quality of Life; Sunitinib; Survival Rate; Thrombocytopenia | 2017 |
A multicenter phase II study of sunitinib in patients with locally advanced or metastatic differentiated, anaplastic or medullary thyroid carcinomas: mature data from the THYSU study.
Topics: Adenocarcinoma, Follicular; Adult; Aged; Angiogenesis Inhibitors; Bone Neoplasms; Carcinoma; Carcinoma, Neuroendocrine; Carcinoma, Papillary; Female; Humans; Indoles; Liver Neoplasms; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Neck; Pyrroles; Sunitinib; Thyroid Cancer, Papillary; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Treatment Outcome | 2017 |
A phase I trial of SJG-136 (NSC#694501) in advanced solid tumors.
Topics: Aged; Antineoplastic Agents; Benzodiazepinones; Colonic Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Tolerance; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Melanoma; Middle Aged; Ovarian Neoplasms; Pyrroles; Urinary Bladder Neoplasms | 2010 |
Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Humans; Indoles; Lung Neoplasms; Male; Middle Aged; Pyrroles; Sunitinib | 2009 |
A phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma: insights into the treatment, efficacy and safety.
Topics: Adult; Aged; Antineoplastic Agents; Bone Neoplasms; Carcinoma, Renal Cell; Female; Humans; Indoles; Japan; Kidney Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Prognosis; Pyrroles; Safety; Sunitinib; Survival Rate; Treatment Outcome | 2010 |
Safety and efficacy of combining sunitinib with bevacizumab + paclitaxel/carboplatin in non-small cell lung cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cohort Studies; Female; Humans; Indoles; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Prognosis; Pyrroles; Safety; Sunitinib; Survival Rate | 2010 |
A phase I study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in solid tumor malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Small Cell; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Indoles; Lung Neoplasms; Male; Maximum Tolerated Dose; Mesylates; Middle Aged; Patient Selection; Proto-Oncogene Proteins c-bcl-2; Pyrroles; Recurrence; Topotecan | 2010 |
Sunitinib in combination with gemcitabine plus cisplatin for advanced non-small cell lung cancer: a phase I dose-escalation study.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Protocols; Deoxycytidine; Disease Progression; Drug Therapy, Combination; Female; Gemcitabine; Humans; Indoles; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Pyrroles; Sunitinib | 2010 |
Sunitinib in pretreated advanced non-small-cell lung carcinoma: a primary result from Asian population.
Topics: Adult; Aged; Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; Female; Humans; Indoles; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Pyrroles; Sunitinib | 2011 |
Biomarker-based phase I dose-escalation, pharmacokinetic, and pharmacodynamic study of oral apricoxib in combination with erlotinib in advanced nonsmall cell lung cancer.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Patient Selection; Prostaglandins; Pyrroles; Quinazolines; Sulfonamides | 2011 |
A Cancer and Leukemia Group B phase II study of sunitinib malate in patients with previously treated metastatic pancreatic adenocarcinoma (CALGB 80603).
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Neoplasms; Female; Humans; Indoles; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Pyrroles; Salvage Therapy; Sunitinib; Survival Rate; Treatment Outcome | 2010 |
The safety and efficacy of sunitinib before planned nephrectomy in metastatic clear cell renal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Bone Neoplasms; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Nephrectomy; Prospective Studies; Pyrroles; Sunitinib; Treatment Outcome; Tumor Burden | 2011 |
[AUO (Working Group on Urological Oncology) study of metastasized renal cell carcinoma: prospective randomized multicenter phase II study on resection of pulmonary metastases in clear cell renal cell carcinoma with or without adjuvant sunitinib therapy ov
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Female; Germany; Humans; Indoles; Kidney Neoplasms; Longitudinal Studies; Lung Neoplasms; Male; Prevalence; Prospective Studies; Pyrroles; Sunitinib; Treatment Outcome | 2011 |
Phase II trial of sunitinib maintenance therapy after platinum-based chemotherapy in patients with extensive-stage small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Early Termination of Clinical Trials; Etoposide; Female; Humans; Indoles; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neovascularization, Pathologic; Patient Dropouts; Platinum; Pyrroles; Small Cell Lung Carcinoma; Sunitinib; Treatment Outcome | 2011 |
Phase II study of sunitinib in patients with non-small cell lung cancer and irradiated brain metastases.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemoradiotherapy; Cranial Irradiation; Female; Follow-Up Studies; Humans; Indoles; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pyrroles; Sunitinib; Survival Rate; Treatment Outcome | 2011 |
A phase II study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in relapsed small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Disease Progression; Female; Humans; Indoles; Lung Neoplasms; Middle Aged; Proto-Oncogene Proteins c-bcl-2; Pyrroles; Recurrence; Thrombocytopenia; Topotecan | 2011 |
Phase I study of sunitinib and erlotinib in advanced nonsquamous non-small cell lung cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Indoles; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Pyrroles; Quinazolines; Sunitinib; Survival Rate; Treatment Outcome | 2011 |
Phase II study of sunitinib as maintenance therapy in patients with locally advanced or metastatic non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Female; Follow-Up Studies; Humans; Indoles; Lung Neoplasms; Maintenance Chemotherapy; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pyrroles; Sunitinib; Survival Analysis | 2011 |
A phase I dose-escalation and pharmacokinetic study of sunitinib in combination with pemetrexed in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Glutamates; Guanine; Humans; Indoles; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Pemetrexed; Pyrroles; Sunitinib; Treatment Outcome | 2012 |
The effect of bexarotene on atorvastatin pharmacokinetics: results from a phase I trial of bexarotene plus chemotherapy in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Atorvastatin; Bexarotene; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Drug Interactions; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertriglyceridemia; Lung Neoplasms; Male; Metabolic Clearance Rate; Middle Aged; Pyrroles; Tetrahydronaphthalenes; Treatment Outcome | 2012 |
Phase I clinical study of the angiogenesis inhibitor TSU-68 combined with carboplatin and paclitaxel in chemotherapy-naive patients with advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Feasibility Studies; Female; Follow-Up Studies; Humans; Indoles; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Oxindoles; Paclitaxel; Propionates; Pyrroles; Tissue Distribution; Treatment Outcome; Young Adult | 2012 |
Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Combinations; Female; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Lactones; Lung Neoplasms; Male; Melanoma; Middle Aged; Pancreatic Neoplasms; Proteasome Inhibitors; Pyrroles; Vorinostat | 2012 |
[Urgent patient admission to Working Group for Urological Oncology (AUO) studies on metastasized renal cell carcinoma needed: prospective randomized multicenter phase II study on resection of pulmonary metastases in clear cell renal cell carcinoma ± adjuv
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Combined Modality Therapy; Female; Germany; Humans; Indoles; Kidney Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Patient Selection; Pyrroles; Sunitinib | 2012 |
A phase I trial of pan-Bcl-2 antagonist obatoclax administered as a 3-h or a 24-h infusion in combination with carboplatin and etoposide in patients with extensive-stage small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Central Nervous System; Drug Administration Schedule; Etoposide; Female; Humans; Indoles; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Proto-Oncogene Proteins c-bcl-2; Pyrroles; Small Cell Lung Carcinoma | 2012 |
Randomised phase II trial of docetaxel and sunitinib in patients with metastatic gastric cancer who were previously treated with fluoropyrimidine and platinum.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Docetaxel; Female; Fluorouracil; Humans; Indoles; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Platinum; Pyrroles; Salvage Therapy; Stomach Neoplasms; Sunitinib; Survival Rate; Taxoids; Tissue Distribution; Treatment Outcome; Young Adult | 2012 |
Phase II study of maintenance sunitinib following irinotecan and carboplatin as first-line treatment for patients with extensive-stage small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Disease Progression; Female; Humans; Indoles; Induction Chemotherapy; Irinotecan; Lung Neoplasms; Maintenance Chemotherapy; Male; Middle Aged; Neoplasm Staging; Pyrroles; Small Cell Lung Carcinoma; Sunitinib; Treatment Outcome | 2012 |
Sunitinib plus erlotinib versus placebo plus erlotinib in patients with previously treated advanced non-small-cell lung cancer: a phase III trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Double-Blind Method; Erlotinib Hydrochloride; Female; Humans; Indoles; Lung Neoplasms; Male; Middle Aged; Placebos; Proportional Hazards Models; Pyrroles; Quinazolines; Smoking; Sunitinib; Treatment Outcome | 2012 |
Sunitinib plus erlotinib for the treatment of advanced/metastatic non-small-cell lung cancer: a lead-in study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cohort Studies; Double-Blind Method; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Indoles; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Pyrroles; Quinazolines; Sunitinib; Survival Rate; Tissue Distribution | 2012 |
Sunitinib combined with pemetrexed and cisplatin: results of a phase I dose-escalation and pharmacokinetic study in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer and mesothelioma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cohort Studies; Female; Glutamates; Guanine; Humans; Indoles; Lung Neoplasms; Male; Mesothelioma; Middle Aged; Pemetrexed; Pyrroles; Sunitinib | 2013 |
A phase II study of sunitinib in patients with relapsed or refractory small cell lung cancer.
Topics: Aged; Antineoplastic Agents; Asthenia; Disease-Free Survival; Female; Humans; Indoles; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Pyrroles; Small Cell Lung Carcinoma; Sunitinib; Thrombocytopenia; Treatment Outcome | 2013 |
Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma and various other solid tumors.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Renal Cell; Female; Gastrointestinal Stromal Tumors; Humans; Indoles; Kidney Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neuroendocrine Tumors; Pyrroles; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Sunitinib | 2008 |
Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cohort Studies; Colorectal Neoplasms; Female; Humans; Indoles; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Peritoneal Neoplasms; Prognosis; Pyrroles; Salvage Therapy; Sunitinib; Survival Rate | 2007 |
Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Cause of Death; Cisplatin; Disease Progression; Drug Administration Schedule; Fatigue; Female; Humans; Indoles; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasm Recurrence, Local; Neoplasm Staging; Pain; Protein-Tyrosine Kinases; Pyrroles; Remission Induction; Stomatitis; Sunitinib; Treatment Outcome | 2008 |
240 other study(ies) available for pyrroles and Lung Neoplasms
| Article | Year |
|---|---|
Discovery and Pharmacological Characterization of JNJ-64619178, a Novel Small-Molecule Inhibitor of PRMT5 with Potent Antitumor Activity.
Topics: Animals; Disease Models, Animal; Enzyme Inhibitors; Humans; Lung Neoplasms; Mice; Protein-Arginine N-Methyltransferases; Pyrimidines; Pyrroles | 2021 |
Transient receptor potential vanilloid 4 promotes the growth of non-small cell lung cancer by regulating Foxp3.
Topics: A549 Cells; Aged; Apoptosis; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Female; Forkhead Transcription Factors; Humans; Leucine; Lung Neoplasms; Male; Middle Aged; Morpholines; Pyrroles; Sulfonamides; TRPV Cation Channels | 2022 |
Trilaciclib (Cosela) for prevention of chemotherapy-related myelosuppression.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Carcinoma, Non-Small-Cell Lung; Drug Interactions; Etoposide; Humans; Lung Neoplasms; Organoplatinum Compounds; Platinum Compounds; Pyrimidines; Pyrroles; Treatment Outcome | 2021 |
Suppression of non-small-cell lung cancer A549 tumor growth by an mtDNA mutation-targeting pyrrole-imidazole polyamide-triphenylphosphonium and a senolytic drug.
Topics: Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; DNA, Mitochondrial; Humans; Imidazoles; Lung Neoplasms; Mutation; Nylons; Pyrroles; Senotherapeutics | 2022 |
Doxorubicin-loaded polypyrrole nanovesicles for suppressing tumor metastasis through combining photothermotherapy and lymphatic system-targeted chemotherapy.
Topics: Animals; Cell Line, Tumor; Doxorubicin; Drug Liberation; Humans; Lung Neoplasms; Lymphatic System; Mice; Nanoparticles; Polymers; Pyrroles | 2022 |
β-Catenin-Specific Inhibitor, iCRT14, Promotes BoHV-1 Infection-Induced DNA Damage in Human A549 Lung Adenocarcinoma Cells by Enhancing Viral Protein Expression.
Topics: A549 Cells; Adenocarcinoma of Lung; beta Catenin; Cell Line, Tumor; DNA Damage; Herpesviridae Infections; Herpesvirus 1, Bovine; Humans; Lung Neoplasms; Pyridines; Pyrroles; Thiazolidinediones; Viral Proteins; Virus Replication | 2022 |
Self-carried nanodrug (SCND-SIS3): A targeted therapy for lung cancer with superior biocompatibility and immune boosting effects.
Topics: Animals; Carcinoma; Cell Line, Tumor; Isoquinolines; Lung Neoplasms; Mice; Nanoparticles; Pyridines; Pyrroles; Signal Transduction; Smad3 Protein; Transforming Growth Factor beta | 2022 |
Modulation of smoke-induced DNA and microRNA alterations in mouse lung by licofelone, a triple COX-1, COX-2 and 5-LOX inhibitor.
Topics: Animals; Anticarcinogenic Agents; Arachidonate 5-Lipoxygenase; Carcinogenesis; Cyclooxygenase 1; Cyclooxygenase 2; Disease Models, Animal; DNA Adducts; DNA Damage; Drug Administration Schedule; Female; Humans; Inflammation; Lung; Lung Neoplasms; Male; Membrane Proteins; Mice; MicroRNAs; Pyrroles; Time Factors; Tobacco Smoke Pollution; Toxicity Tests, Subchronic | 2020 |
Photo-Uncaging of a Microtubule-Targeted Rigidin Analogue in Hypoxic Cancer Cells and in a Xenograft Mouse Model.
Topics: A549 Cells; Alkaloids; Animals; Antineoplastic Agents; Cell Proliferation; Humans; Light; Lung Neoplasms; Mice, Nude; Microtubules; Oxygen; Prodrugs; Pyrimidines; Pyrroles; Tubulin Modulators; Tumor Hypoxia | 2019 |
USP14 Inhibition Regulates Tumorigenesis by Inducing Autophagy in Lung Cancer In Vitro.
Topics: Autophagy; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Transformation, Neoplastic; Humans; Lung Neoplasms; Pyrroles; RNA Interference; RNA, Small Interfering; Ubiquitin Thiolesterase | 2019 |
Prediction of cytotoxic activity of a series of 1H-pyrrolo[2,3-b]pyridine derivatives as possible inhibitors of c-Met using molecular fingerprints.
Topics: A549 Cells; Antineoplastic Agents; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Lung Neoplasms; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Structure; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyridines; Pyrroles; Quantitative Structure-Activity Relationship | 2019 |
CDK7 Inhibition Potentiates Genome Instability Triggering Anti-tumor Immunity in Small Cell Lung Cancer.
Topics: Animals; Antineoplastic Agents; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Chemokine CXCL9; Cyclin-Dependent Kinase-Activating Kinase; Cyclin-Dependent Kinases; DNA Damage; Female; Genomic Instability; Humans; Immune System; Inflammation; Interferon-gamma; Lung Neoplasms; Male; Mice; Micronucleus Tests; Programmed Cell Death 1 Receptor; Pyrazoles; Pyrroles; Signal Transduction; Small Cell Lung Carcinoma; Tumor Necrosis Factor-alpha | 2020 |
CM082, a novel angiogenesis inhibitor, enhances the antitumor activity of gefitinib on epidermal growth factor receptor mutant non-small cell lung cancer in vitro and in vivo.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Drug Synergism; Drug Therapy, Combination; ErbB Receptors; Female; Gefitinib; Humans; Indoles; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Mutation; Pyrroles; Pyrrolidines; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2020 |
Dual TTK/CLK2 inhibitor, CC-671, selectively antagonizes ABCG2-mediated multidrug resistance in lung cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily G, Member 2; Benzamides; Binding Sites; Cell Cycle Proteins; Cell Line, Tumor; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Lung Neoplasms; Molecular Docking Simulation; Neoplasm Proteins; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles | 2020 |
Biomimetic nanoparticle loading obatoclax mesylate for the treatment of non-small-cell lung cancer (NSCLC) through suppressing Bcl-2 signaling.
Topics: A549 Cells; Animals; Antineoplastic Agents; Apoptosis; Biomimetics; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Delayed-Action Preparations; Drug Compounding; Drug Liberation; Drug Stability; Humans; Indoles; Lung Neoplasms; Male; Mice, Inbred C57BL; Nanoparticles; Polylactic Acid-Polyglycolic Acid Copolymer; Proto-Oncogene Proteins c-bcl-2; Pyrroles; Signal Transduction; Solubility; Xenograft Model Antitumor Assays | 2020 |
A Case of Extracellular Signal-Regulated Kinase Inhibitor-Associated Retinopathy.
Topics: Aminopyridines; Extracellular Signal-Regulated MAP Kinases; Female; Fluorescein Angiography; Fundus Oculi; Humans; Lung Neoplasms; Middle Aged; Pyrroles; Retina; Retinal Diseases; Tomography, Optical Coherence | 2020 |
Aptamer-based electrochemical biosensing strategy toward human non-small cell lung cancer using polyacrylonitrile/polypyrrole nanofibers.
Topics: A549 Cells; Acrylic Resins; Aptamers, Nucleotide; Biosensing Techniques; Carcinoma, Non-Small-Cell Lung; Dielectric Spectroscopy; Electrodes; HeLa Cells; Humans; Limit of Detection; Lung Neoplasms; Nanofibers; Polymers; Pyrroles | 2020 |
Evaluating
Topics: Actinium; Alpha Particles; Animals; Antibodies, Monoclonal; Antigens, Neoplasm; Benzodiazepines; Beta Particles; Female; HEK293 Cells; Humans; Immunoconjugates; Immunoglobulin G; Intracellular Signaling Peptides and Proteins; Lung Neoplasms; Lutetium; Maximum Tolerated Dose; Membrane Proteins; Mice; Mice, Inbred NOD; Mice, SCID; Pyrroles; Radioisotopes; Small Cell Lung Carcinoma; Treatment Outcome; Tumor Burden; Xenograft Model Antitumor Assays | 2020 |
Enhanced anticancer effect of ROS-boosted photothermal therapy by using fucoidan-coated polypyrrole nanoparticles.
Topics: Animals; Cell Line, Tumor; Humans; Light; Lung Neoplasms; Mice; Mice, Nude; Nanoparticles; P-Selectin; Photothermal Therapy; Polymers; Polysaccharides; Pyrroles; Reactive Oxygen Species; Vascular Endothelial Growth Factor A | 2021 |
Combinations of proteasome inhibitors with obatoclax are effective for small cell lung cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Bortezomib; Cell Line, Tumor; Drug Synergism; Forkhead Box Protein M1; HEK293 Cells; Humans; Indoles; Lung Neoplasms; Mice, Nude; Myeloid Cell Leukemia Sequence 1 Protein; Oligopeptides; Proteasome Inhibitors; Pyrroles; Small Cell Lung Carcinoma; Up-Regulation; Xenograft Model Antitumor Assays | 2021 |
Local Targeting of Lung-Tumor-Associated Macrophages with Pulmonary Delivery of a CSF-1R Inhibitor for the Treatment of Breast Cancer Lung Metastases.
Topics: Administration, Inhalation; Administration, Intravenous; Aminopyridines; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Disease Models, Animal; Drug Screening Assays, Antitumor; Drug Synergism; Female; Humans; Lung Neoplasms; Mice; Paclitaxel; Phosphorylation; Pyrroles; Receptors, Granulocyte-Macrophage Colony-Stimulating Factor; Tumor Microenvironment; Tumor-Associated Macrophages | 2020 |
Third-generation EGFR inhibitor HS-10296 in combination with famitinib, a multi-targeted tyrosine kinase inhibitor, exerts synergistic antitumor effects through enhanced inhibition of downstream signaling in EGFR-mutant non-small cell lung cancer cells.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Indoles; Lung Neoplasms; Protein Kinase Inhibitors; Pyrroles; Receptor Protein-Tyrosine Kinases; Signal Transduction | 2021 |
Synergistic effects of type I PRMT and PARP inhibitors against non-small cell lung cancer cells.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Cells, Cultured; DNA Damage; Drug Synergism; Enzyme Inhibitors; Ethylenediamines; Humans; Lung Neoplasms; Protein-Arginine N-Methyltransferases; Purine-Nucleoside Phosphorylase; Pyrroles | 2021 |
Role of AMPK and Akt in triple negative breast cancer lung colonization.
Topics: AMP-Activated Protein Kinases; Animals; Apoptosis; Cell Line, Tumor; Energy Metabolism; Female; Heterocyclic Compounds, 3-Ring; Humans; Lung Neoplasms; Mice; Mice, Inbred NOD; Mice, SCID; Neoplasm Invasiveness; Neoplastic Cells, Circulating; Proto-Oncogene Proteins c-akt; Pyrimidines; Pyrroles; RNA Interference; RNA, Small Interfering; Signal Transduction; Triple Negative Breast Neoplasms | 2021 |
New Drug Protects Against Myelosuppression Secondary to Lung Cancer Chemotherapy.
Topics: Antineoplastic Agents, Alkylating; Bone Marrow; Dose-Response Relationship, Drug; Humans; Leukopenia; Lung Neoplasms; Neutropenia; Pyrimidines; Pyrroles; Small Cell Lung Carcinoma | 2021 |
Pyoluteorin Induces Apoptosis and Autophagy in NSCLC Cells.
Topics: Antineoplastic Agents; Apoptosis; Autophagy; Beclin-1; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Humans; Lung Neoplasms; MAP Kinase Signaling System; Phenols; Proto-Oncogene Proteins c-bcl-2; Pyrroles | 2021 |
The synthesis and bioactivity of pyrrolo[2,3-d]pyrimidine derivatives as tyrosine kinase inhibitors for NSCLC cells with EGFR mutations.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; ErbB Receptors; Humans; Lung Neoplasms; Molecular Docking Simulation; Molecular Structure; Mutation; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Structure-Activity Relationship | 2021 |
A novel polyaniline/polypyrrole/graphene oxide fiber for the determination of volatile organic compounds in headspace gas of lung cell lines.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aniline Compounds; Cells, Cultured; Fibroblasts; Graphite; Humans; Lung Neoplasms; Polymers; Pyrroles; Solid Phase Microextraction; Volatile Organic Compounds | 2017 |
Durable Control of Metastatic AKT1-Mutant WHO Grade 1 Meningothelial Meningioma by the AKT Inhibitor, AZD5363.
Topics: Adult; Antineoplastic Agents; Female; Humans; Lung Neoplasms; Meningeal Neoplasms; Meningioma; Mutation; Neoplasm Grading; Proto-Oncogene Proteins c-akt; Pyrimidines; Pyrroles; Tumor Cells, Cultured | 2017 |
Dihydroberberine exhibits synergistic effects with sunitinib on NSCLC NCI-H460 cells by repressing MAP kinase pathways and inflammatory mediators.
Topics: A549 Cells; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Berberine; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Humans; Indoles; Inflammation Mediators; Lung Neoplasms; MAP Kinase Signaling System; Mice, Inbred NOD; Mice, SCID; Pyrroles; Sunitinib; Tumor Burden; Xenograft Model Antitumor Assays | 2017 |
Depletion of Tumor-Associated Macrophages with a CSF-1R Kinase Inhibitor Enhances Antitumor Immunity and Survival Induced by DC Immunotherapy.
Topics: Aminopyridines; Animals; Antigens, Neoplasm; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Dendritic Cells; Disease Models, Animal; Humans; Immunotherapy, Adoptive; Lung Neoplasms; Macrophages; Mesothelioma; Mesothelioma, Malignant; Neoplasm Invasiveness; Programmed Cell Death 1 Receptor; Protein Kinase Inhibitors; Pyrroles; Receptor, Macrophage Colony-Stimulating Factor | 2017 |
Synthetic 8-hydroxydeoxyguanosine inhibited metastasis of pancreatic cancer through concerted inhibitions of ERM and Rho-GTPase.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; 8-Hydroxy-2'-Deoxyguanosine; Acetylcysteine; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Claudin-1; Deoxyguanosine; DNA-Binding Proteins; Epithelial-Mesenchymal Transition; Focal Adhesion Kinase 1; Gene Expression Regulation, Neoplastic; GTPase-Activating Proteins; Humans; Hyaluronan Receptors; Imidazoles; Lung Neoplasms; Matrix Metalloproteinases; Mice; Mice, Nude; NADPH Oxidases; Pancreatic Neoplasms; Pyrroles; rho-Associated Kinases; Signal Transduction; Transcription Factors; Vimentin; Xenograft Model Antitumor Assays; Zonula Occludens-1 Protein | 2017 |
Retrospective evaluation of toceranib (Palladia) treatment for canine metastatic appendicular osteosarcoma.
Topics: Animals; Bone Neoplasms; Dog Diseases; Dogs; Female; Indoles; Lung Neoplasms; Male; Osteosarcoma; Pyrroles; Retrospective Studies; Treatment Outcome | 2017 |
EZH2 Modifies Sunitinib Resistance in Renal Cell Carcinoma by Kinome Reprogramming.
Topics: Animals; Antineoplastic Agents; Bevacizumab; Carcinoma, Renal Cell; Cell Line, Tumor; Drug Resistance, Neoplasm; Enhancer of Zeste Homolog 2 Protein; Female; Humans; Indoles; Kidney Neoplasms; Lung Neoplasms; Mice; Mice, Inbred ICR; Mice, SCID; Neovascularization, Pathologic; Phosphorylation; Pyrroles; Receptor Protein-Tyrosine Kinases; Sunitinib; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2017 |
Prognostic effect of cytoreductive nephrectomy in synchronous metastatic renal cell carcinoma: a comparative study using inverse probability of treatment weighting.
Topics: Aged; Anilides; Antibodies, Monoclonal; Antineoplastic Agents; Carcinoma, Renal Cell; Cohort Studies; Combined Modality Therapy; Cytoreduction Surgical Procedures; Female; Humans; Indazoles; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Nephrectomy; Nivolumab; Probability; Prognosis; Proportional Hazards Models; Pyridines; Pyrimidines; Pyrroles; Retrospective Studies; Sex Factors; Sulfonamides; Sunitinib; Survival Rate; Thrombocytosis | 2018 |
Vitamin D derivatives potentiate the anticancer and anti-angiogenic activity of tyrosine kinase inhibitors in combination with cytostatic drugs in an A549 non-small cell lung cancer model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Becaplermin; Calcitriol; Carcinoma, Non-Small-Cell Lung; Cholecalciferol; Cisplatin; Cytostatic Agents; Dihydroxycholecalciferols; Docetaxel; Female; Humans; Imatinib Mesylate; Indoles; Lung Neoplasms; Mice, SCID; Proto-Oncogene Proteins c-sis; Pyrroles; Sunitinib; Taxoids; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2018 |
Effects of Glycogen Synthase Kinase-3β Inhibitor TWS119 on Proliferation and Cytokine Production of TILs From Human Lung Cancer.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; CD8-Positive T-Lymphocytes; Cell Differentiation; Cell Proliferation; Cytokines; Female; Glycogen Synthase Kinase 3 beta; Humans; Immunologic Memory; Immunotherapy, Adoptive; Lung Neoplasms; Lymphocytes, Tumor-Infiltrating; Male; Middle Aged; Pyrimidines; Pyrroles; Wnt Signaling Pathway | 2018 |
Autophagy Inhibition Enhances SPCA-1 Cell Proliferation Inhibition Induced by By-1 from the Stout Camphor Medicinal Mushroom, Taiwanofungus camphoratus (Agaricomycetes).
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Agaricales; Antineoplastic Agents; Autophagy; Carcinoma, Non-Small-Cell Lung; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cell Survival; Culture Media; Humans; Lung Neoplasms; Pyrroles | 2018 |
Antitumor activity of BJ-1207, a 6-amino-2,4,5-trimethylpyridin-3-ol derivative, in human lung cancer.
Topics: A549 Cells; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Chickens; Chorioallantoic Membrane; Humans; Indoles; Lung Neoplasms; NADPH Oxidases; Pyridines; Pyrroles; Reactive Oxygen Species; Signal Transduction; Structure-Activity Relationship; Sunitinib; Transplantation, Heterologous | 2018 |
Rogaratinib: A potent and selective pan-FGFR inhibitor with broad antitumor activity in FGFR-overexpressing preclinical cancer models.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Colorectal Neoplasms; Drug Screening Assays, Antitumor; Female; Human Umbilical Vein Endothelial Cells; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms; Phosphorylation; Piperazines; Pyrroles; Random Allocation; Rats; Receptors, Fibroblast Growth Factor; Thiophenes; Xenograft Model Antitumor Assays | 2019 |
Biofunctional core-shell polypyrrole-polyethylenimine nanocomplex for a locally sustained photothermal with reactive oxygen species enhanced therapeutic effect against lung cancer.
Topics: Cell Communication; Cell Line, Tumor; Cell Survival; Fluorescence; Humans; Hyperthermia, Induced; Lung Neoplasms; Nanostructures; Phototherapy; Polyethyleneimine; Polymers; Pyrroles; Reactive Oxygen Species; Surface Properties | 2019 |
Novel hyaluronic acid-modified temperature-sensitive nanoparticles for synergistic chemo-photothermal therapy.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Contrast Media; Docetaxel; Drug Carriers; Drug Liberation; Female; Fluorescent Dyes; Humans; Hyaluronic Acid; Infrared Rays; Injections, Intravenous; Lung; Lung Neoplasms; Mice, Inbred BALB C; Nanoparticles; Particle Size; Phospholipids; Photoacoustic Techniques; Polymers; Pyrroles; Temperature; Theranostic Nanomedicine | 2019 |
Effect of platinum‑based chemotherapy on the expression of natural killer group 2 member D ligands, programmed cell death‑1 ligand 1 and HLA class I in non‑small cell lung cancer.
Topics: Aged; Antineoplastic Agents; Apoptosis; B7-H1 Antigen; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Cisplatin; Cytotoxicity, Immunologic; Drug Resistance, Neoplasm; Drug Therapy, Combination; Female; Follow-Up Studies; Gene Expression Regulation, Neoplastic; GPI-Linked Proteins; Histocompatibility Antigens Class I; Humans; Intercellular Signaling Peptides and Proteins; Janus Kinases; Killer Cells, Natural; Ligands; Lung Neoplasms; Male; Middle Aged; NK Cell Lectin-Like Receptor Subfamily K; Piperidines; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; STAT Transcription Factors; Tumor Cells, Cultured | 2019 |
Presumptive primary intrathoracic mast cell tumours in two dogs.
Topics: Animals; Antineoplastic Agents; Carcinoma; Dog Diseases; Dogs; Female; Indoles; Lung Neoplasms; Mast Cells; Pyrroles; Thoracic Neoplasms; Thoracic Wall | 2019 |
Sunitinib for the treatment of metastatic paraganglioma and vasoactive intestinal polypeptide-producing tumor (VIPoma).
Topics: Abdominal Neoplasms; Aged; Antineoplastic Agents; Biomarkers, Tumor; Child; Drug Administration Schedule; Female; Humans; Indoles; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Magnetic Resonance Imaging; Male; Pancreatic Neoplasms; Paraganglioma; Protein Kinase Inhibitors; Pyrroles; Sunitinib; Time Factors; Treatment Outcome; Vipoma | 2013 |
[A case of complete response of multiple lung metastases of renal cell carcinoma with the flexible administration of sunitinib].
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Drug Administration Schedule; Humans; Indoles; Kidney Neoplasms; Lung Neoplasms; Male; Pyrroles; Sunitinib | 2013 |
βArrestin-1 and Mcl-1 modulate self-renewal growth of cancer stem-like side-population cells in non-small cell lung cancer.
Topics: Animals; Arrestins; beta-Arrestins; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Humans; Indoles; Lung; Lung Neoplasms; Mice; Myeloid Cell Leukemia Sequence 1 Protein; Neoplastic Stem Cells; Proto-Oncogene Proteins c-bcl-2; Pyrroles | 2013 |
Improvement of actinic keratosis associated with sunitinib therapy for metastatic renal cell carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indoles; Keratosis, Actinic; Kidney Neoplasms; Lung Neoplasms; Male; Pancreatic Neoplasms; Pyrroles; Sunitinib | 2013 |
Long-lasting clinical benefit of sunitinib malate in the treatment of a case of heavily pre-treated metastatic liposarcoma.
Topics: Aged; Antineoplastic Agents; Humans; Indoles; Liposarcoma; Lung Neoplasms; Male; Mutation; Neck; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrroles; Receptors, Platelet-Derived Growth Factor; Sunitinib | 2013 |
Anti-angiogenic and anti-metastatic activity of synthetic phosphoethanolamine.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Renal Cell; Caspase 3; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cyclin D1; Cytoskeleton; Ethanolamines; Gene Expression Regulation, Neoplastic; Human Umbilical Vein Endothelial Cells; Humans; Indoles; Kidney Tubules, Proximal; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mitochondria; Neoplasm Metastasis; Neovascularization, Pathologic; Oxidation-Reduction; Pyrroles; Rats; Sunitinib; Transcription, Genetic; Vascular Endothelial Growth Factor Receptor-1; Wound Healing | 2013 |
Discovery of Rho-kinase inhibitors by docking-based virtual screening.
Topics: Animals; Antineoplastic Agents; Atorvastatin; Breast Neoplasms; Cell Line, Tumor; Cerebral Hemorrhage; Drug Evaluation, Preclinical; Drug Screening Assays, Antitumor; Female; HeLa Cells; Heptanoic Acids; Humans; Lung Neoplasms; Models, Molecular; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Structure; Multiple Myeloma; Protein Kinase Inhibitors; Pyrroles; rho-Associated Kinases; Zebrafish | 2013 |
Long-term response to sunitinib therapy for metastatic renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Bone Neoplasms; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indoles; Kidney Neoplasms; Lung Neoplasms; Male; Middle Aged; Pyrroles; Retrospective Studies; Sunitinib; Treatment Outcome; Young Adult | 2013 |
Antiangiogenic therapy promoted metastasis of hepatocellular carcinoma by suppressing host-derived interleukin-12b in mouse models.
Topics: Angiogenesis Inhibitors; Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Dendritic Cells; Diphosphonates; Heterografts; Humans; Imidazoles; Immunosuppression Therapy; Indoles; Interleukin-12 Subunit p40; Killer Cells, Natural; Liver Neoplasms; Lung Neoplasms; Macrophages; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Knockout; Mice, Nude; Neoplasm Transplantation; Neoplastic Cells, Circulating; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; Zoledronic Acid | 2013 |
Acute tubular necrosis associated with mTOR inhibitor therapy: a real entity biopsy-proven.
Topics: Acute Kidney Injury; Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Carcinoma, Renal Cell; Cisplatin; Cyclophosphamide; Diphosphonates; Doxorubicin; Female; Glutamates; Guanine; Humans; Imidazoles; Indoles; Interferons; Kidney Tubules; Lung Neoplasms; Lymphoma, B-Cell; Male; Mediastinal Neoplasms; Middle Aged; Necrosis; Nephrectomy; Pemetrexed; Prednisone; Pyrroles; Sunitinib; TOR Serine-Threonine Kinases; Vincristine; Zoledronic Acid | 2013 |
[Case of multiple lung metastases of renal cell carcinoma failing to respond to Interferon-alpha (IFN-alpha) and sunitinib but markedly responding to everolimus].
Topics: Carcinoma, Renal Cell; Endoscopy; Everolimus; Humans; Immunosuppressive Agents; Indoles; Interferon-alpha; Kidney Neoplasms; Lung Neoplasms; Male; Middle Aged; Nephrectomy; Pneumonectomy; Pyrroles; Sirolimus; Sunitinib; Tomography, X-Ray Computed; Treatment Failure; Treatment Outcome | 2013 |
Systematic combination screening reveals synergism between rapamycin and sunitinib against human lung cancer.
Topics: Angiogenesis Inhibitors; Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Chick Embryo; Chorioallantoic Membrane; Drug Screening Assays, Antitumor; Drug Synergism; G1 Phase Cell Cycle Checkpoints; Gene Expression; Human Umbilical Vein Endothelial Cells; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Indoles; Inhibitory Concentration 50; Lung Neoplasms; Phosphorylation; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-akt; Pyrroles; Rats; Rats, Sprague-Dawley; Signal Transduction; Sirolimus; Sunitinib; Tissue Culture Techniques; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A | 2014 |
Atorvastatin overcomes gefitinib resistance in KRAS mutant human non-small cell lung carcinoma cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Atorvastatin; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Class I Phosphatidylinositol 3-Kinases; Drug Resistance, Neoplasm; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Gefitinib; Heptanoic Acids; Humans; Lung Neoplasms; Mice; Mutation; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-raf; Proto-Oncogene Proteins p21(ras); Pyrroles; Quinazolines; ras Proteins; Signal Transduction; Xenograft Model Antitumor Assays | 2013 |
The evaluation of efficacy and safety of sunitinib on EGFR-TKI pretreated advanced non-small cell lung cancer patients in China.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; China; Disease-Free Survival; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Follow-Up Studies; Humans; Indoles; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Protein-Tyrosine Kinases; Pyrroles; Receptor, ErbB-2; Retrospective Studies; Sunitinib; Survival Rate; Treatment Outcome | 2014 |
Sunitinib in malignant melanoma: a treatment option only for KIT-mutated patients?
Topics: Aged; Biomarkers, Pharmacological; Carcinoma, Renal Cell; Humans; Indoles; Liver Neoplasms; Lung Neoplasms; Male; Melanoma; Mutation; Proto-Oncogene Proteins c-kit; Pyrroles; Skin Neoplasms; Sunitinib | 2013 |
PF-3758309, p21-activated kinase 4 inhibitor, suppresses migration and invasion of A549 human lung cancer cells via regulation of CREB, NF-κB, and β-catenin signalings.
Topics: beta Catenin; Cell Line, Tumor; Cell Movement; Cyclic AMP Response Element-Binding Protein; Down-Regulation; Extracellular Matrix; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Neoplasm Invasiveness; NF-kappa B; p21-Activated Kinases; Pyrazoles; Pyrroles; Signal Transduction | 2014 |
[Brain metastasis which appeared during complete response of lung metastatic lesion by sunitinib treatment in a patient with renal cell carcinoma].
Topics: Antineoplastic Agents; Brain Neoplasms; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Lung Neoplasms; Male; Middle Aged; Pyrroles; Remission Induction; Sunitinib | 2013 |
Tyrosine kinase inhibitor treatments in patients with metastatic thyroid carcinomas: a retrospective study of the TUTHYREF network.
Topics: Adenocarcinoma; Adenocarcinoma, Follicular; Adenoma, Oxyphilic; Adult; Aged; Antineoplastic Agents; Bone Neoplasms; Carcinoma; Carcinoma, Neuroendocrine; Carcinoma, Papillary; Disease-Free Survival; Female; Humans; Indoles; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Piperidines; Pleural Neoplasms; Protein-Tyrosine Kinases; Pyrroles; Quinazolines; Retrospective Studies; Sorafenib; Sunitinib; Thyroid Cancer, Papillary; Thyroid Neoplasms; Treatment Outcome | 2014 |
American Society of Clinical Oncology Annual Meeting 2013.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Docetaxel; Erlotinib Hydrochloride; Female; Humans; Imidazoles; Indoles; Lung Neoplasms; Male; Medical Oncology; Multicenter Studies as Topic; Oximes; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Quinazolines; Randomized Controlled Trials as Topic; Small Cell Lung Carcinoma; Societies, Medical; Sulfones; Sunitinib; Taxoids; Treatment Outcome; Triazoles; United States | 2013 |
Organ-specific and tumor-size-dependent responses to sunitinib in clear cell renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Lung Neoplasms; Male; Middle Aged; Organ Specificity; Pyrroles; Retrospective Studies; Sunitinib; Treatment Outcome; Tumor Burden | 2014 |
Metastatic hepatic epithelioid hemangio-endothelioma: long-term response to sunitinib malate.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Female; Hemangioendothelioma, Epithelioid; Humans; Indoles; Liver Neoplasms; Longitudinal Studies; Lung Neoplasms; Male; Neovascularization, Pathologic; Pyrroles; Sunitinib; Treatment Outcome | 2014 |
Predictive role of tissue-based molecular markers in patients treated with sunitinib for metastatic renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers; Bone Neoplasms; Brain Neoplasms; Carcinoma, Renal Cell; Cohort Studies; Female; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Nephrectomy; Predictive Value of Tests; Proto-Oncogene Proteins c-sis; Pyrroles; Receptor, Platelet-Derived Growth Factor beta; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2015 |
Uncommon side effect with a commonly used targeted agent: sunitinib-induced nephrotic syndrome in a patient with metastatic renal cell carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Drug Administration Schedule; Female; Humans; Indoles; Kidney Neoplasms; Lung Neoplasms; Nephrotic Syndrome; Prognosis; Protein-Tyrosine Kinases; Pyrroles; Sunitinib | 2014 |
Hydrogen-bonded and reduction-responsive micelles loading atorvastatin for therapy of breast cancer metastasis.
Topics: Animals; Atorvastatin; Breast; Breast Neoplasms; Cell Line, Tumor; Delayed-Action Preparations; Female; Heptanoic Acids; Humans; Hydrogen Bonding; Hydrophobic and Hydrophilic Interactions; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Liver Neoplasms; Lung; Lung Neoplasms; Mice, Inbred BALB C; Mice, Nude; Micelles; Oxidation-Reduction; Polyethylene Glycols; Pyrroles; Vitamin E | 2014 |
Inhibition of Hedgehog signalling by NVP-LDE225 (Erismodegib) interferes with growth and invasion of human renal cell carcinoma cells.
Topics: Actin Cytoskeleton; Actins; Animals; Antineoplastic Combined Chemotherapy Protocols; Biphenyl Compounds; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Synergism; Everolimus; Hedgehog Proteins; Humans; Indoles; Inhibitory Concentration 50; Kidney Neoplasms; Kruppel-Like Transcription Factors; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Mitogen-Activated Protein Kinases; Neoplasm Micrometastasis; Nuclear Proteins; Paxillin; Proto-Oncogene Proteins c-akt; Pyridines; Pyrroles; Receptors, G-Protein-Coupled; Ribosomal Protein S6 Kinases, 70-kDa; Signal Transduction; Sirolimus; Smoothened Receptor; Sunitinib; Transcription Factors; Tumor Burden; Xenograft Model Antitumor Assays; Zinc Finger Protein GLI1; Zinc Finger Protein Gli2 | 2014 |
Statins do not alter the incidence of mesothelioma in asbestos exposed mice or humans.
Topics: Adult; Aged; Animals; Anti-Inflammatory Agents, Non-Steroidal; Asbestos; Atorvastatin; Cohort Studies; Cyclooxygenase 2 Inhibitors; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Lung Neoplasms; Male; Mesothelioma; Mice; Mice, Transgenic; Middle Aged; Pyrroles | 2014 |
Tumor xenograft uptake of a pyrrole-imidazole (Py-Im) polyamide varies as a function of cell line grafted.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Collagen; Drug Combinations; Humans; Imidazoles; Laminin; Lung Neoplasms; Male; Mice, Inbred BALB C; Nylons; Prostatic Neoplasms; Proteoglycans; Pyrroles; Tissue Distribution; Xenograft Model Antitumor Assays | 2014 |
Acute aortic dissection in a patient with metastatic renal cell carcinoma treated with axitinib.
Topics: Antineoplastic Agents; Aortic Aneurysm, Thoracic; Aortic Dissection; Axitinib; Carcinoma, Renal Cell; ErbB Receptors; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Pyrroles; Sunitinib | 2015 |
Modulation by licofelone and celecoxib of experimentally induced cancer and preneoplastic lesions in mice exposed to cigarette smoke.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Body Weight; Celecoxib; Cyclooxygenase 2 Inhibitors; Enzyme Inhibitors; Female; Lung Neoplasms; Male; Mice; Neoplasms, Experimental; Precancerous Conditions; Pyrroles; Smoking; Survival Rate; Toxicity Tests, Subchronic | 2015 |
Sunitinib: the next advance in small-cell lung cancer?
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Indoles; Lung Neoplasms; Male; Pyrroles; Small Cell Lung Carcinoma | 2015 |
Kidney cancer: SWITCHing inconsequential.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyrroles | 2015 |
A case of metastatic renal cell carcinoma and bile duct carcinoma treated with a combination of sunitinib and gemcitabine.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Carcinoma, Renal Cell; Cholangiopancreatography, Magnetic Resonance; Deoxycytidine; Female; Gemcitabine; Humans; Indoles; Kidney Neoplasms; Lung Neoplasms; Neoplasm Metastasis; Neoplasms, Second Primary; Polymorphism, Single Nucleotide; Pyrroles; Sunitinib; Tomography, X-Ray Computed; Treatment Outcome | 2015 |
[Efficacy of Sunitinib Rechallenge in Metastatic Renal Cell Carcinoma : A Case Report].
Topics: Aged; Antineoplastic Agents; Bone Neoplasms; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Lung Neoplasms; Nephrectomy; Pyrroles; Recurrence; Sunitinib; Tomography, X-Ray Computed | 2015 |
Sorafenib-Sunitinib Sequence: The Jury Is Out.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib | 2015 |
Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Neoplasms; Carcinoma, Papillary; Carcinoma, Renal Cell; Female; Follow-Up Studies; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Pyrroles; Retrospective Studies; Sunitinib; Survival Rate | 2015 |
Rapid Response to Sunitinib in a Patient with Lung Adenocarcinoma Harboring KIF5B-RET Fusion Gene.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Female; Humans; Indoles; Lung Neoplasms; Middle Aged; Oncogene Proteins, Fusion; Pyrroles; Sunitinib | 2015 |
In vitro baselining of new pyrrolopyrimidine EGFR-TK inhibitors with Erlotinib.
Topics: Antineoplastic Agents; Breast Neoplasms; Caco-2 Cells; Cell Line, Tumor; Cell Proliferation; Cytochrome P-450 Enzyme Inhibitors; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; In Vitro Techniques; Lung Neoplasms; Ovarian Neoplasms; Pyrimidines; Pyrroles | 2015 |
Sunitinib monotherapy instead of mitotane combination therapy for the treatment of refractory adrenocortical carcinoma.
Topics: Adrenocortical Carcinoma; Adult; Antineoplastic Agents; Chemotherapy, Adjuvant; Female; Humans; Indoles; Lung Neoplasms; Mitotane; Multiple Pulmonary Nodules; Nephrectomy; Pyrroles; Sunitinib; Tomography, X-Ray Computed | 2015 |
Absence of Significant Correlation of Adverse Events Between First- and Second-Line Tyrosine Kinase Inhibitors in Patients With Metastatic Renal Cell Carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Female; Humans; Imidazoles; Indazoles; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Lung Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib | 2016 |
[PATHOLOGICAL COMPLETE RESPONSE WITH EVEROLIMUS FOR MULTIPLE LUNG METASTASES OF RENAL CELL CARCINOMA RESISTANT TO SUNITINIB].
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Drug Resistance, Neoplasm; Everolimus; Humans; Indoles; Kidney Neoplasms; Lung Neoplasms; Male; Middle Aged; Pyrroles; Remission Induction; Sunitinib; Tomography, X-Ray Computed | 2015 |
ADC Shows Effectiveness in SCLC.
Topics: Antibodies, Monoclonal; Benzodiazepines; Humans; Immunoconjugates; Intracellular Signaling Peptides and Proteins; Lung Neoplasms; Membrane Proteins; Pyrroles; Retreatment; Small Cell Lung Carcinoma; Treatment Outcome | 2015 |
More on sunitinib 2 weeks on/1 week off schedule: the Rainbow analysis.
Topics: Bone Neoplasms; Carcinoma, Papillary; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Male; Pyrroles | 2016 |
More colors to the palette.
Topics: Bone Neoplasms; Carcinoma, Papillary; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Male; Pyrroles | 2016 |
Aptasensor based on fluorescence resonance energy transfer for the analysis of adenosine in urine samples of lung cancer patients.
Topics: Adenosine; Aptamers, Nucleotide; Biosensing Techniques; Fluorescence; Fluorescence Resonance Energy Transfer; G-Quadruplexes; Humans; Limit of Detection; Lung Neoplasms; Molecular Dynamics Simulation; Polymers; Pyrroles; Quantum Dots | 2016 |
Outcomes for Patients with Metastatic Renal Cell Carcinoma Achieving a Complete Response on Targeted Therapy: A Registry-based Analysis.
Topics: Aged; Antineoplastic Agents; Bevacizumab; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Registries; Response Evaluation Criteria in Solid Tumors; Sorafenib; Sulfonamides; Sunitinib; Survival Rate; Treatment Outcome; Withholding Treatment | 2016 |
Discovery of 1-{(3R,4R)-3-[({5-Chloro-2-[(1-methyl-1H-pyrazol-4-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}oxy)methyl]-4-methoxypyrrolidin-1-yl}prop-2-en-1-one (PF-06459988), a Potent, WT Sparing, Irreversible Inhibitor of T790M-Containing EGFR Mutants.
Topics: Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Discovery; ErbB Receptors; Humans; Lung Neoplasms; Models, Molecular; Molecular Structure; Mutant Proteins; Mutation; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Structure-Activity Relationship; Tumor Cells, Cultured | 2016 |
A two kinase-gene signature model using CDK2 and PAK4 expression predicts poor outcome in non-small cell lung cancers.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Cyclin-Dependent Kinase 2; Disease-Free Survival; Female; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Lung Neoplasms; Male; Middle Aged; p21-Activated Kinases; Pyrazoles; Pyrroles; Tissue Array Analysis; Treatment Outcome | 2016 |
Synergistic Effect of Anti-Angiogenic and Radiation Therapy: Quantitative Evaluation with Dynamic Contrast Enhanced MR Imaging.
Topics: Angiogenesis Inhibitors; Animals; Cell Line, Tumor; Combined Modality Therapy; Contrast Media; Gadolinium DTPA; Humans; Indoles; Lung Neoplasms; Magnetic Resonance Imaging; Mice; Mice, Inbred BALB C; Mice, Nude; Muscle, Skeletal; Neoplasms, Experimental; Pyrroles; Random Allocation; Sunitinib; Thigh; Transplantation, Heterotopic; Tumor Burden; Xenograft Model Antitumor Assays | 2016 |
Thyroid Transcription Factor 1 Reprograms Angiogenic Activities of Secretome.
Topics: A549 Cells; Angiogenic Proteins; Antibodies; Blotting, Western; Cell Hypoxia; Cell Line, Tumor; Cell Survival; Culture Media, Conditioned; Cytokines; Enzyme-Linked Immunosorbent Assay; Exosomes; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Indoles; Lung Neoplasms; Neovascularization, Physiologic; Nuclear Proteins; Promoter Regions, Genetic; Pyrroles; Real-Time Polymerase Chain Reaction; RNA Interference; RNA, Small Interfering; Thyroid Nuclear Factor 1; TOR Serine-Threonine Kinases; Transcription Factors; Up-Regulation; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2 | 2016 |
Schedule-dependent cytotoxicity of sunitinib and TRAIL in human non-small cell lung cancer cells with or without EGFR and KRAS mutations.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Administration Schedule; Drug Resistance, Neoplasm; ErbB Receptors; Genes, erbB-1; Humans; Indoles; Lung Neoplasms; Mutation; Proto-Oncogene Proteins p21(ras); Pyrroles; Sunitinib; TNF-Related Apoptosis-Inducing Ligand | 2016 |
CT halo sign and crazy paving pattern due to lung metastases hemorrhage after sunitinib therapy.
Topics: Angiogenesis Inhibitors; Hemorrhage; Humans; Indoles; Kidney Neoplasms; Lung Neoplasms; Male; Middle Aged; Pyrroles; Sunitinib; Tomography, X-Ray Computed | 2017 |
MCL-1 is the key target of adjuvant chemotherapy to reverse the cisplatin-resistance in NSCLC.
Topics: Antineoplastic Agents; bcl-2 Homologous Antagonist-Killer Protein; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; Drug Therapy, Combination; Humans; Indoles; Inhibitory Concentration 50; Lung Neoplasms; Myeloid Cell Leukemia Sequence 1 Protein; Proto-Oncogene Proteins c-bcl-2; Pyrroles | 2016 |
Preclinical PK/PD model for combined administration of erlotinib and sunitinib in the treatment of A549 human NSCLC xenograft mice.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Computer Simulation; Drug Dosage Calculations; Drug Synergism; Erlotinib Hydrochloride; Female; Indoles; Lung Neoplasms; Mice; Mice, Nude; Models, Biological; Pyrroles; Sunitinib; Xenograft Model Antitumor Assays | 2016 |
[Inhibitory effect of imrecoxib combined with lobaplatin on tumor growth and lymph node metastasis of human lung cancer xenografts in nude mice].
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cadherins; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cyclobutanes; Cytoskeletal Proteins; Heterografts; Humans; Lung Neoplasms; Lymph Nodes; Male; Mice; Mice, Nude; Neoplasm Proteins; Organoplatinum Compounds; Pyrroles; Random Allocation; RNA, Messenger; Sulfides; Transplantation, Heterologous; Tumor Burden | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; Bone Neoplasms; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease-Free Survival; Humans; Imidazoles; Indazoles; Indoles; Interferon-alpha; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Prognosis; Proportional Hazards Models; Pyrroles; Remission Induction; Retrospective Studies; Sirolimus; Sorafenib; Sunitinib; Survival Rate; Treatment Outcome; Tumor Burden | 2016 |
A novel strategy for highly efficient isolation and analysis of circulating tumor-specific cell-free DNA from lung cancer patients using a reusable conducting polymer nanostructure.
Topics: Cell Line; Cell Line, Tumor; Circulating Tumor DNA; Equipment Design; ErbB Receptors; Exons; Genes, erbB-1; Humans; Lab-On-A-Chip Devices; Lung Neoplasms; Nanostructures; Point Mutation; Polymers; Pyrroles | 2016 |
Paratesticular Metastasis of a Clear-Cell Renal-Cell Carcinoma With Renal Vein Thrombus Mimicking Primary Testicular Cancer.
Topics: Carcinoma, Renal Cell; Diagnosis, Differential; Humans; Indoles; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Nephrectomy; Orchiectomy; Pyrroles; Sunitinib; Testicular Neoplasms; Thrombectomy; Treatment Outcome; Venous Thrombosis | 2017 |
Chronic exposure to cigarette smoke leads to activation of p21 (RAC1)-activated kinase 6 (PAK6) in non-small cell lung cancer cells.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; ErbB Receptors; Gene Silencing; Humans; Lung Neoplasms; Male; Mice; Mice, Inbred NOD; Mice, SCID; Neoplasm Transplantation; p21-Activated Kinases; Phosphorylation; Proteome; Pyrazoles; Pyrroles; rac1 GTP-Binding Protein; RNA, Small Interfering; Signal Transduction; Smoke; Tobacco Products | 2016 |
A retrospective analysis of 14 consecutive Chinese patients with unresectable or metastatic alveolar soft part sarcoma treated with sunitinib.
Topics: Adolescent; Adult; Antineoplastic Agents; Bone Neoplasms; China; Female; Follow-Up Studies; Humans; Indoles; Lung Neoplasms; Lymphatic Metastasis; Male; Neoadjuvant Therapy; Prognosis; Pyrroles; Retrospective Studies; Sarcoma, Alveolar Soft Part; Sunitinib; Survival Rate; Young Adult | 2016 |
[Complete response to tyrosine kinase inhibitors in metastatic renal cancer. Report of four cases].
Topics: Aged; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Female; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Remission Induction; Sunitinib | 2016 |
High Potency VEGFRs/MET/FMS Triple Blockade by TAS-115 Concomitantly Suppresses Tumor Progression and Bone Destruction in Tumor-Induced Bone Disease Model with Lung Carcinoma Cells.
Topics: A549 Cells; Animals; Bone Neoplasms; Cell Differentiation; Cell Proliferation; Crizotinib; Disease Models, Animal; Humans; Indoles; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Osteoclasts; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrazoles; Pyridines; Pyrroles; Quinolines; RANK Ligand; Receptor, Macrophage Colony-Stimulating Factor; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sunitinib; Thiourea; Tibia; Transplantation, Heterologous; X-Ray Microtomography | 2016 |
Vessel co-option is common in human lung metastases and mediates resistance to anti-angiogenic therapy in preclinical lung metastasis models.
Topics: Angiogenesis Inhibitors; Capillaries; Humans; Immunotherapy; Indoles; Lung Neoplasms; Models, Biological; Neovascularization, Pathologic; Pyrroles; Sunitinib | 2017 |
EGF Induced RET Inhibitor Resistance in CCDC6-RET Lung Cancer Cells.
Topics: Adenocarcinoma; Cell Line, Tumor; Cetuximab; Drug Resistance, Neoplasm; Epidermal Growth Factor; ErbB Receptors; fms-Like Tyrosine Kinase 3; Gefitinib; Gene Rearrangement; Hepatocyte Growth Factor; Humans; Indoles; Lung Neoplasms; MAP Kinase Signaling System; Mutation; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Mas; Proto-Oncogene Proteins c-ret; Pyrroles; Quinazolines; RNA, Small Interfering; Signal Transduction; Sorafenib; Sunitinib | 2017 |
Pharmacokinetic-Pharmacodynamic Modeling of the Anti-Tumor Effect of Sunitinib Combined with Dopamine in the Human Non-Small Cell Lung Cancer Xenograft.
Topics: A549 Cells; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Dopamine; Drug Synergism; Drug Therapy, Combination; Female; Humans; Indoles; Lung Neoplasms; Mice; Mice, Nude; Pyrroles; Sunitinib; Xenograft Model Antitumor Assays | 2017 |
Metastatic renal clear cell carcinoma to the rectum, lungs, ilium, and lymph nodes: A case report.
Topics: Aged; Antineoplastic Agents; Bone Neoplasms; Carcinoma, Renal Cell; Humans; Ilium; Indoles; Kidney Neoplasms; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Nephrectomy; Pyrroles; Rectal Neoplasms; Sunitinib | 2017 |
TREATMENT OF RENAL CARCINOMA IN A BINTURONG (ARCTICTIS BINTURONG) WITH NEPHRECTOMY AND A TYROSINE KINASE INHIBITOR.
Topics: Animals; Animals, Zoo; Carcinoma, Renal Cell; Carnivora; Female; Indoles; Kidney Neoplasms; Lung Neoplasms; Pyrroles | 2016 |
Assessment of response to anti-angiogenic targeted therapy in pulmonary metastatic renal cell carcinoma: R2* value as a predictive biomarker.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Lung Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Niacinamide; Observer Variation; Phenylurea Compounds; Pyrroles; Reproducibility of Results; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; ROC Curve; Sorafenib; Sunitinib; Tomography, X-Ray Computed; Treatment Outcome | 2017 |
Heterogeneity of macrophage infiltration and therapeutic response in lung carcinoma revealed by 3D organ imaging.
Topics: Aminopyridines; Animals; Antineoplastic Agents; Carcinoma, Lewis Lung; Cell Line, Tumor; Female; Humans; Imaging, Three-Dimensional; Lung; Lung Neoplasms; Macrophage Colony-Stimulating Factor; Macrophages; Mice; Mice, Inbred C57BL; Microscopy, Confocal; Microscopy, Fluorescence; Nanoparticles; Perfusion; Pyrroles; RAW 264.7 Cells; Receptors, Granulocyte-Macrophage Colony-Stimulating Factor; Signal Transduction; Tomography, X-Ray Computed; Treatment Outcome; Tumor Burden; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2017 |
Allergic broncho-pulmonary aspergillosis following treatment with an anti-programmed cell death protein 1 monoclonal antibody therapy.
Topics: Antibodies, Monoclonal, Humanized; Aspergillosis, Allergic Bronchopulmonary; Carcinoma, Renal Cell; Humans; Immunocompromised Host; Immunosuppressive Agents; Indoles; Kidney Neoplasms; Lung Neoplasms; Male; Middle Aged; Programmed Cell Death 1 Receptor; Pyrroles; Sunitinib | 2017 |
Long-term results of therapy with sunitinib in metastatic alveolar soft part sarcoma.
Topics: Adult; Aged; Bone Neoplasms; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Hand-Foot Syndrome; Humans; Indoles; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Pyrroles; Sarcoma, Alveolar Soft Part; Sunitinib | 2017 |
Case records of the Massachusetts General Hospital. Case 17-2008. A 63-year-old man with metastatic renal-cell carcinoma.
Topics: Adrenal Gland Neoplasms; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Combined Modality Therapy; Diagnosis, Differential; Fatal Outcome; Humans; Indoles; Kidney Neoplasms; Lung Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Staging; Nephrectomy; Prognosis; Pyrroles; Sunitinib | 2008 |
Synergistic inhibition of lung tumorigenesis by a combination of green tea polyphenols and atorvastatin.
Topics: Animals; Apoptosis; Atorvastatin; Catechin; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Female; Flavonoids; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lung Neoplasms; Mice; Phenols; Plant Extracts; Polyphenols; Pyrroles; Tea | 2008 |
Worsening of osteonecrosis of the jaw during treatment with sunitinib in a patient with metastatic renal cell carcinoma.
Topics: Carcinoma, Renal Cell; Dental Fistula; Humans; Indoles; Jaw Diseases; Kidney Neoplasms; Lung Neoplasms; Male; Middle Aged; Osteonecrosis; Pyrroles; Sunitinib | 2009 |
Flare-up: an often unreported phenomenon nevertheless familiar to oncologists prescribing tyrosine kinase inhibitors.
Topics: Bone Neoplasms; Carcinoma, Renal Cell; Disease Progression; Drug Administration Schedule; Female; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Middle Aged; Nephrectomy; Pain; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Sunitinib; Tomography, X-Ray Computed | 2009 |
Synthesis of novel substituted pyrazole-5-carbohydrazide hydrazone derivatives and discovery of a potent apoptosis inducer in A549 lung cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Crystallography, X-Ray; Humans; Hydrazines; Lung Neoplasms; Molecular Conformation; Pyrroles | 2009 |
Tyrosine kinase inhibitors in treatment of fibrous histiocytoma.
Topics: Antineoplastic Agents; Bone Neoplasms; Histiocytoma, Malignant Fibrous; Humans; Indoles; Kidney Neoplasms; Lung; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Sunitinib | 2009 |
Sunitinib treatment for patients with advanced clear-cell renal-cell carcinoma after progression on sorafenib.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Bone Neoplasms; Brain Neoplasms; Carcinoma, Renal Cell; Disease Progression; Female; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Prospective Studies; Pyridines; Pyrroles; Salvage Therapy; Sorafenib; Sunitinib; Survival Rate; Treatment Outcome | 2009 |
Sunitinib prolongs survival in genetically engineered mouse models of multistep lung carcinogenesis.
Topics: AMP-Activated Protein Kinases; Angiogenesis Inhibitors; Animals; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Disease Models, Animal; Genetic Engineering; Immunohistochemistry; Indoles; Lung Neoplasms; Mice; Mutation; Neoplasm Metastasis; Neovascularization, Pathologic; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins p21(ras); Pyrroles; Sunitinib | 2009 |
[Necrotizing hand-foot skin reaction induced by antiangiogenic in a patient with Thevenard neuroacropathy].
Topics: Angiogenesis Inhibitors; Anti-Bacterial Agents; Antineoplastic Agents; Female; Foot; Hand; Hereditary Sensory and Autonomic Neuropathies; Humans; Indoles; Kidney Neoplasms; Lung Neoplasms; Middle Aged; Necrosis; Pyrroles; Skin Ulcer; Sunitinib | 2009 |
Ligand-dependent platelet-derived growth factor receptor (PDGFR)-alpha activation sensitizes rare lung cancer and sarcoma cells to PDGFR kinase inhibitors.
Topics: Antibodies; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Gene Amplification; Gene Expression Profiling; Humans; Indoles; Ligands; Lung Neoplasms; Lymphokines; Platelet-Derived Growth Factor; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Rhabdomyosarcoma; RNA, Small Interfering; Sunitinib | 2009 |
Metastatic adamantinoma responds to treatment with receptor tyrosine kinase inhibitor.
Topics: Accidents, Traffic; Adamantinoma; Antineoplastic Agents; Appendicitis; Enzyme Inhibitors; Foot; Fractures, Bone; Humans; Immunohistochemistry; Indoles; Lung Neoplasms; Male; Middle Aged; Psoriasis; Pyrroles; Receptor Protein-Tyrosine Kinases; Smoking; Sunitinib; Tomography, X-Ray Computed; Vitamin B 12 Deficiency | 2010 |
The reverse side of the victory: flare up of symptoms after discontinuation of sunitinib or sorafenib in renal cell cancer patients. A report of three cases.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Nephrectomy; Niacinamide; Phenylurea Compounds; Pleural Neoplasms; Pyridines; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome | 2009 |
Synthesis and antiproliferative activity of 2,4-disubstituted 6-aryl-7H-pyrrolo[3,2-d]pyrimidin-7-one 5-oxides.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Humans; Lung Neoplasms; Oxides; Pyrimidines; Pyrroles | 2009 |
Effects of antalarmin and nadolol on the relationship between social stress and pulmonary metastasis development in male OF1 mice.
Topics: Adrenergic beta-Antagonists; Aggression; Animals; Central Nervous System Agents; Corticosterone; Interferon-gamma; Lung; Lung Neoplasms; Male; Mice; Mice, Inbred Strains; Nadolol; Neoplasms, Experimental; Pyrimidines; Pyrroles; Random Allocation; Receptors, Corticotropin-Releasing Hormone; Social Behavior; Stress, Psychological | 2009 |
Successful sunitinib treatment of metastatic renal cell carcinoma in a patient with end stage renal disease on hemodialysis.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indoles; Kidney Failure, Chronic; Kidney Neoplasms; Lung Neoplasms; Male; Middle Aged; Pyrroles; Renal Dialysis; Sunitinib; Treatment Outcome | 2009 |
Spontaneous pyopneumothorax in patients treated with mTOR inhibitors for subpleural pulmonary metastases.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Calcitonin; Carcinoma, Renal Cell; Combined Modality Therapy; Disease Susceptibility; Everolimus; Fatal Outcome; Female; Humans; Indoles; Kidney Neoplasms; Lung Neoplasms; Male; Middle Aged; Necrosis; Neoplasm Proteins; Nephrectomy; Niacinamide; Phenylurea Compounds; Pneumonia, Bacterial; Pneumothorax; Protein Precursors; Pyridines; Pyrroles; Rupture, Spontaneous; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases | 2010 |
Advances in personalized therapeutics in non-small cell lung cancer: 4q12 amplification, PDGFRA oncogene addiction and sunitinib sensitivity.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Humans; Indoles; Lung Neoplasms; Precision Medicine; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Sunitinib | 2009 |
Aortic dissection in a patient treated by sunitinib for metastatic renal cell carcinoma.
Topics: Antihypertensive Agents; Antineoplastic Agents; Aortic Aneurysm; Aortic Dissection; Carcinoma, Renal Cell; Combined Modality Therapy; Humans; Hypertension; Indoles; Kidney Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Nephrectomy; Pyrroles; Sirolimus; Sunitinib | 2010 |
Sunitinib paves the way for targeted therapies in neuroendocrine tumors.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoid Tumor; Cell Line, Tumor; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Indoles; Kidney Neoplasms; Lung Neoplasms; Melphalan; Neovascularization, Pathologic; Neuroendocrine Tumors; Pancreatic Neoplasms; Procarbazine; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrroles; Sunitinib; Vinblastine; Xenograft Model Antitumor Assays | 2009 |
Mechanism of action of an imidopiperidine inhibitor of human polynucleotide kinase/phosphatase.
Topics: Adenosine Triphosphate; Antineoplastic Agents, Phytogenic; Binding Sites; Camptothecin; Cell Survival; Circular Dichroism; DNA Ligase ATP; DNA Ligases; DNA Polymerase beta; DNA Repair; DNA Repair Enzymes; Drug Resistance, Neoplasm; Enzyme Inhibitors; Etoposide; Fluorescence Resonance Energy Transfer; Humans; Lung Neoplasms; Mutagenesis, Site-Directed; Phosphotransferases (Alcohol Group Acceptor); Photoelectron Spectroscopy; Piperidines; Poly-ADP-Ribose Binding Proteins; Protein Conformation; Pyrroles; Radiation-Sensitizing Agents; Tumor Cells, Cultured; Xenopus Proteins | 2010 |
Good response to second-line bevacizumab and interferon-alpha in a sunitinib-refractory patient with metastatic renal cell carcinoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Renal Cell; Female; Humans; Indoles; Interferon-alpha; Kidney Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Prognosis; Pyrroles; Salvage Therapy; Sunitinib; Treatment Outcome | 2010 |
Inhibition of tyrosine kinases by sunitinib associated with focal segmental glomerulosclerosis lesion in addition to thrombotic microangiopathy.
Topics: Aged; Antineoplastic Agents; Biopsy; Carcinoma, Renal Cell; Enalapril; Glomerulosclerosis, Focal Segmental; Humans; Indoles; Kidney; Kidney Neoplasms; Lung Neoplasms; Male; Protein-Tyrosine Kinases; Pyrroles; Sunitinib; Thrombotic Microangiopathies | 2010 |
An exploratory study of sunitinib plus paclitaxel as first-line treatment for patients with advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Female; Humans; Indoles; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Pilot Projects; Pyrroles; Sunitinib; Survival Rate; Tissue Distribution; Treatment Outcome | 2010 |
Renal cell carcinoma: complete response.
Topics: Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Radiography; Smoking; Sunitinib; Thrombocytopenia; Treatment Outcome | 2010 |
Bronchial fistula associated with sunitinib in a patient previously treated with radiation therapy.
Topics: Adult; Antineoplastic Agents; Bronchial Fistula; Bronchial Neoplasms; Carcinoma, Renal Cell; Combined Modality Therapy; Humans; Indoles; Kidney Neoplasms; Lung Neoplasms; Male; Mediastinal Neoplasms; Pyrroles; Sunitinib | 2010 |
Synergistic antitumor effect of TRAIL in combination with sunitinib in vitro and in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Colonic Neoplasms; Drug Screening Assays, Antitumor; Drug Synergism; Humans; Indoles; Lung Neoplasms; Male; Mice; Mice, Nude; Pyrroles; Sunitinib; TNF-Related Apoptosis-Inducing Ligand; Xenograft Model Antitumor Assays | 2010 |
Choi response criteria for early prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Neoplasms; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Pyrroles; Sunitinib; Survival Rate; Tomography, X-Ray Computed; Treatment Outcome; Young Adult | 2010 |
Plasma N-terminal pro-brain natriuretic peptide as prognostic marker in fatal cardial decompensation with sunitinib malate therapy.
Topics: Aged; Carcinoma, Renal Cell; Echocardiography; Heart Failure; Humans; Indoles; Kidney Neoplasms; Lung Neoplasms; Male; Natriuretic Peptide, Brain; Neoplasm Metastasis; Prognosis; Pyrroles; Retrospective Studies; Sunitinib; Thrombosis | 2010 |
Triple molecular target approach to selective melanoma cytotoxicity.
Topics: Animals; Antineoplastic Agents; Benzimidazoles; Catalytic Domain; Cell Line, Tumor; Humans; IMP Dehydrogenase; Lung Neoplasms; Melanoma; Mice; Mice, SCID; Models, Molecular; Phenylalanine; Pyrroles; Quantitative Structure-Activity Relationship; Xenograft Model Antitumor Assays | 2010 |
Ongoing under-reporting of clinically relevant safety data in phase II studies of tyrosine kinase inhibitors.
Topics: Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Humans; Indoles; Lung Neoplasms; Protein Kinase Inhibitors; Pyrroles; Research Design; Sunitinib; Treatment Outcome | 2010 |
Leptomeningeal carcinomatosis from renal cell cancer: treatment attempt with radiation and sunitinib (case report).
Topics: Aged; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Renal Cell; Combined Modality Therapy; Fatal Outcome; Humans; Indoles; Kidney Neoplasms; Lung Neoplasms; Magnetic Resonance Imaging; Male; Meningeal Carcinomatosis; Pyrroles; Radiotherapy Dosage; Sunitinib; Tomography, X-Ray Computed | 2010 |
Abscess formation mimicking disease progression, in a patient with metastatic renal cell carcinoma during sunitinib treatment.
Topics: Abdominal Abscess; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Disease Progression; Humans; Indoles; Kidney Neoplasms; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Prognosis; Pyrroles; Sunitinib | 2010 |
Necrosis of a skin autograft after short-term treatment with sunitinib in a 14-year-old girl with metastatic alveolar soft part sarcoma of the thigh.
Topics: Adolescent; Angiogenesis Inhibitors; Antineoplastic Agents; Chemotherapy, Adjuvant; Combined Modality Therapy; Compassionate Use Trials; Female; Follow-Up Studies; Humans; Indoles; Lung Neoplasms; Necrosis; Postoperative Complications; Pyrroles; Radiotherapy, Adjuvant; Reoperation; Sarcoma, Alveolar Soft Part; Skin Transplantation; Soft Tissue Neoplasms; Sunitinib; Surgical Flaps; Thigh | 2010 |
Long-term stable disease in metastatic renal cell carcinoma: sorafenib sequenced to sunitinib and everolimus: a case study.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Everolimus; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Pyridines; Pyrroles; Randomized Controlled Trials as Topic; Sirolimus; Sorafenib; Sunitinib | 2011 |
Metastatic renal cell carcinoma complicated with diffuse alveolar hemorrhage: a rare adverse effect of sunitinib.
Topics: Aged; Antineoplastic Agents; Bronchoalveolar Lavage Fluid; Carcinoma, Renal Cell; Hemorrhage; Humans; Indoles; Kidney Neoplasms; Lung Neoplasms; Male; Pulmonary Alveoli; Pyrroles; Sunitinib; Tomography, X-Ray Computed | 2010 |
Treatment of multidrug resistant advanced alveolar soft part sarcoma with sunitinib.
Topics: Adult; Angiogenesis Inhibitors; Antineoplastic Agents; Bone Neoplasms; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Indoles; Lung Neoplasms; Male; Pyrroles; Quality of Life; Sarcoma, Alveolar Soft Part; Sunitinib; Treatment Outcome | 2012 |
Metastatic collecting duct carcinoma of the kidney responded to sunitinib.
Topics: Bone Neoplasms; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Lung Neoplasms; Middle Aged; Neoplasm Metastasis; Protein Kinase Inhibitors; Pyrroles; Ribs; Sunitinib | 2011 |
Evolution of an adenocarcinoma in response to selection by targeted kinase inhibitors.
Topics: Adenocarcinoma; Benzenesulfonates; Gene Dosage; Gene Expression Regulation, Neoplastic; Genes, Neoplasm; High-Throughput Nucleotide Sequencing; Humans; Indoles; Lung Neoplasms; Mitogen-Activated Protein Kinases; Mutation; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-ret; Pyridines; Pyrroles; Selection, Genetic; Sorafenib; Sunitinib; Tongue Neoplasms | 2010 |
Long-term response with everolimus for metastatic renal cell carcinoma refractory to sunitinib.
Topics: Aged; Antineoplastic Agents; Arthritis, Rheumatoid; Carcinoma, Renal Cell; Clinical Trials, Phase III as Topic; Everolimus; Humans; Hypercholesterolemia; Hypertension; Indoles; Kidney Neoplasms; Lung Neoplasms; Male; Pyrroles; Randomized Controlled Trials as Topic; Salvage Therapy; Sirolimus; Sunitinib | 2011 |
Evidence-based urology in practice: randomized controlled trials stopped early for benefit.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Evidence-Based Medicine; Female; Humans; Indoles; Kidney Neoplasms; Lung Neoplasms; Nephrectomy; Pyrroles; Randomized Controlled Trials as Topic; Sunitinib | 2010 |
Recall pneumonitis during systemic treatment with sunitinib.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Lung Neoplasms; Lymphocytes; Mediastinal Neoplasms; Middle Aged; Neoplasms, Radiation-Induced; Pneumonia; Prognosis; Pyrroles; Sunitinib; Tomography, X-Ray Computed | 2010 |
Renal cell carcinoma and acute promyelocytic leukemia: a nonrandom association?
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Colonic Neoplasms; Colonic Polyps; Cytarabine; Daunorubicin; Doxorubicin; Female; Humans; Idarubicin; Indoles; Kidney Neoplasms; Leukemia, Promyelocytic, Acute; Lung Neoplasms; Male; Mercaptopurine; Methotrexate; Middle Aged; Neoplasms, Second Primary; Pyrroles; Remission Induction; Sunitinib; Time Factors; Tretinoin | 2010 |
Severe rhabdomyolysis during sunitinib treatment of metastatic renal cell carcinoma. A report of two cases.
Topics: Aged; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Male; Pyrroles; Renal Dialysis; Rhabdomyolysis; Sunitinib; Treatment Outcome | 2010 |
Brain natriuretic peptide precursor (NT-pro-BNP) levels predict for clinical benefit to sunitinib treatment in patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers; Bone Neoplasms; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Prognosis; Pyrroles; Sunitinib | 2010 |
[Leg ulcerations and sunitinib].
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Chemotherapy, Adjuvant; Combined Modality Therapy; Drug Eruptions; Female; Humans; Indoles; Kidney Neoplasms; Leg Ulcer; Liver Neoplasms; Lung Neoplasms; Pyrroles; Risk Factors; Sarcoma; Sunitinib; Venous Thrombosis | 2010 |
Fatal necrotizing pancreatitis during combined treatment with erlotinib and sunitinib.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Fatal Outcome; Female; Humans; Indoles; Lung Neoplasms; Middle Aged; Pancreatitis, Acute Necrotizing; Pyrroles; Quinazolines; Sunitinib | 2010 |
Synthesis and biological evaluation of polyenylpyrrole derivatives as anticancer agents acting through caspases-dependent apoptosis.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Caspases; Cell Line, Tumor; Drug Screening Assays, Antitumor; Female; Humans; Lung Neoplasms; Mice; Mice, Nude; Mitochondria; Neoplasm Transplantation; Polyenes; Pyrroles; Stereoisomerism; Structure-Activity Relationship; Transplantation, Heterologous | 2010 |
PDGFR signaling blockade in marrow stroma impairs lung cancer bone metastasis.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Apoptosis; Bone Marrow Cells; Bone Neoplasms; Cell Adhesion; Cell Line; Cell Proliferation; Gene Expression Profiling; Humans; Indoles; Lung Neoplasms; Mice; Neoplasm Invasiveness; Pyrroles; Receptors, Platelet-Derived Growth Factor; Signal Transduction; Stromal Cells; Sunitinib | 2011 |
Dual functional monoclonal antibody PF-04605412 targets integrin alpha5beta1 and elicits potent antibody-dependent cellular cytotoxicity.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibody-Dependent Cell Cytotoxicity; Bevacizumab; Endothelial Cells; Haplorhini; HEK293 Cells; Humans; Immunoglobulin Fc Fragments; Immunoglobulin G; Indoles; Integrin alpha5beta1; Killer Cells, Natural; Lung Neoplasms; Macrophages; Mice; Mice, Inbred BALB C; Mice, SCID; Mice, Transgenic; NIH 3T3 Cells; Phagocytosis; Pyrroles; Receptors, IgG; Sunitinib | 2010 |
A case study of metastatic Xp11.2 translocation renal cell carcinoma effectively treated with sunitinib.
Topics: Adult; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Carcinoma, Renal Cell; Chromosomes, Human, X; Female; Humans; Indoles; Kidney Neoplasms; Lung Neoplasms; Pyrroles; Sunitinib; Translocation, Genetic | 2011 |
Response and safety of sunitinib in a heavily pre-treated metastatic non-small cell lung carcinoma patient.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Humans; Indoles; Lung Neoplasms; Male; Pyrroles; Sunitinib | 2010 |
Cyclooxygenase-2 up-regulates vascular endothelial growth factor via a protein kinase C pathway in non-small cell lung cancer.
Topics: Adult; Aged; Carbazoles; Carcinoma, Non-Small-Cell Lung; Cell Survival; Cyclic AMP-Dependent Protein Kinases; Cyclooxygenase 2; Enzyme Activators; Female; Humans; Lung Neoplasms; Male; Middle Aged; Prostaglandins E; Protein Kinase C; Pyrroles; Tetradecanoylphorbol Acetate; Tumor Cells, Cultured; Up-Regulation; Vascular Endothelial Growth Factor A; Xanthones | 2011 |
Nasal metastases from renal cell carcinoma are associated with Memorial Sloan-Kettering Cancer Center poor-prognosis classification.
Topics: Antineoplastic Agents; Bone Neoplasms; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Lung Neoplasms; Male; Middle Aged; Nephrectomy; Nose Neoplasms; Pyrroles; Skull Neoplasms; Sunitinib; Tomography, X-Ray Computed | 2011 |
CYR61 downregulation reduces osteosarcoma cell invasion, migration, and metastasis.
Topics: Animals; Apoptosis; Atorvastatin; Bone and Bones; Cell Line; Cell Movement; Cell Proliferation; Cell Survival; Cysteine-Rich Protein 61; Down-Regulation; Gene Expression Regulation, Neoplastic; Heptanoic Acids; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Neoplasm Invasiveness; Osteosarcoma; Prenylation; Pyrroles | 2011 |
Concurrent and sequential administration of sunitinib malate and docetaxel in human non-small cell lung cancer cells and xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Proliferation; Cells, Cultured; Docetaxel; Human Umbilical Vein Endothelial Cells; Humans; Immunoblotting; Indoles; Lung Neoplasms; Mice; Mice, Nude; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Phosphorylation; Pyrroles; Sunitinib; Taxoids; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2012 |
Long-term response and postsurgical complete remissions after treatment with sunitinib malate, an oral multitargeted receptor tyrosine kinase inhibitor, in patients with metastatic renal cell carcinoma.
Topics: Administration, Oral; Adrenal Gland Neoplasms; Adrenalectomy; Aged; Angiogenesis Inhibitors; Bone Neoplasms; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Female; Humans; Indoles; Kidney Neoplasms; Lung Neoplasms; Lymph Node Excision; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Staging; Nephrectomy; Osteotomy; Pneumonectomy; Protein Kinase Inhibitors; Pyrroles; Sunitinib; Time Factors; Treatment Outcome | 2011 |
Optimization of circulating biomarkers of obatoclax-induced cell death in patients with small cell lung cancer.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Blood Chemical Analysis; Calibration; Cell Death; Cell Line, Tumor; Cell Proliferation; Cisplatin; Clinical Trials, Phase I as Topic; Drug Synergism; Etoposide; Humans; Indoles; Lung Neoplasms; Prognosis; Pyrroles; Small Cell Lung Carcinoma | 2011 |
Response to sunitinib in an adult patient with rhabdoid renal cell carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Cell Dedifferentiation; Combined Modality Therapy; Female; Humans; Hypothyroidism; Indoles; Kidney Neoplasms; Lung Neoplasms; Middle Aged; Nephrectomy; Peripheral Nervous System Diseases; Protein Kinase Inhibitors; Pyrroles; Remission Induction; Rhabdoid Tumor; Sunitinib | 2011 |
[Clinical case of the month. A patient with advanced non-small-cell lung cancer presenting with an exceptional response to targeted therapies].
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Humans; Indoles; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Pyrroles; Quinazolines; Sunitinib | 2011 |
Chemopreventive efficacy and mechanism of licofelone in a mouse lung tumor model via aspiration.
Topics: Adenoma; Animals; Anticarcinogenic Agents; Biological Assay; Biomarkers, Tumor; Disease Models, Animal; Disease Progression; Drug Delivery Systems; Female; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mice; Models, Chemical; Pyrroles | 2011 |
Design, synthesis and biological evaluation of novel 4-thiazolidinones containing indolin-2-one moiety as potential antitumor agent.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Drug Design; Drug Screening Assays, Antitumor; Female; Fibroblasts; Humans; Indoles; Inhibitory Concentration 50; Liver Neoplasms; Lung Neoplasms; Pyrroles; Sunitinib; Thiazolidines | 2011 |
Lung Aspergillosis in renal cell carcinoma patient treated with sunitinib.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indoles; Lung Neoplasms; Male; Opportunistic Infections; Pulmonary Aspergillosis; Pyrroles; Sunitinib; Tomography, X-Ray Computed | 2012 |
Efficacy of re-challenging metastatic renal cell carcinoma with mTOR inhibitors.
Topics: Antineoplastic Agents; Benzimidazoles; Carcinoma, Renal Cell; Everolimus; Humans; Indoles; Kidney Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pyrroles; Quinolones; Sirolimus; Sunitinib; TOR Serine-Threonine Kinases | 2011 |
Sunitinib-induced acute psychosis: case report.
Topics: Aged; Bipolar Disorder; Carcinoma, Renal Cell; Combined Modality Therapy; Female; Humans; Indoles; Kidney Neoplasms; Lung Neoplasms; Psychotic Disorders; Pyrroles; Sunitinib | 2011 |
Metastatic collecting duct carcinoma of the kidney treated with sunitinib.
Topics: Antineoplastic Agents; Biopsy; Bone Neoplasms; Carcinoma, Renal Cell; Diagnosis, Differential; Fatal Outcome; Follow-Up Studies; Humans; Indoles; Kidney Neoplasms; Lung Neoplasms; Male; Middle Aged; Nephrectomy; Pyrroles; Ribs; Sunitinib | 2011 |
Synergistic interaction between sunitinib and docetaxel is sequence dependent in human non-small lung cancer with EGFR TKIs-resistant mutation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Docetaxel; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Humans; Indoles; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Pyrroles; Sunitinib; Taxoids; Time Factors | 2011 |
Hypertension as a predictive factor for survival outcomes in patients with metastatic renal cell carcinoma treated with sunitinib after progression on cytokines.
Topics: Adult; Aged; Antineoplastic Agents; Bone Neoplasms; Carcinoma, Renal Cell; Cohort Studies; Cytokines; Disease Progression; Disease-Free Survival; Humans; Hypertension; Indoles; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Predictive Value of Tests; Pyrroles; Retrospective Studies; Sunitinib; Treatment Outcome | 2012 |
Flare up of symptoms after discontinuation of sunitinib in patient with lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Administration, Oral; Antineoplastic Agents; Combined Modality Therapy; Disease Progression; Female; Humans; Indoles; Lung Neoplasms; Middle Aged; Neoplasm Metastasis; Pyrroles; Sunitinib; Treatment Outcome; Withholding Treatment | 2011 |
Renal carcinoma with (6;11)(p21;q12) translocation: report of an adult case.
Topics: Antineoplastic Combined Chemotherapy Protocols; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Biomarkers, Tumor; Carcinoma, Renal Cell; Cathepsin K; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 6; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Indoles; Interferons; Kidney Neoplasms; Lung Neoplasms; Male; Middle Aged; Oncogene Proteins, Fusion; Pyrroles; Sirolimus; Sunitinib; Translocation, Genetic | 2011 |
Sunitinib-induced nephrotic syndrome in association with drug response in a patient with Xp11.2 translocation renal cell carcinoma.
Topics: Adult; Antineoplastic Agents; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Carcinoma, Renal Cell; Chromosomes, Human, X; Combined Modality Therapy; Female; Gene Fusion; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Nephrectomy; Nephrotic Syndrome; Pyrroles; Sunitinib; Translocation, Genetic; Treatment Outcome | 2011 |
Synthetic prodiginine obatoclax (GX15-070) and related analogues: anion binding, transmembrane transport, and cytotoxicity properties.
Topics: Animals; Anions; Antineoplastic Agents; Apoptosis; Biological Transport; Cattle; Cell Line, Tumor; Crystallography, X-Ray; Humans; Indoles; Ion Transport; Ionophores; Liposomes; Lung Neoplasms; Magnetic Resonance Spectroscopy; Prodigiosin; Proto-Oncogene Proteins c-bcl-2; Pyrroles; Tumor Cells, Cultured | 2011 |
Atorvastatin reduces vascular endothelial growth factor (VEGF) expression in human non-small cell lung carcinomas (NSCLCs) via inhibition of reactive oxygen species (ROS) production.
Topics: Animals; Apoptosis; Atorvastatin; Carcinoma, Non-Small-Cell Lung; Catalase; Cell Line, Tumor; Cell Membrane; Female; Glutathione Peroxidase; Heptanoic Acids; Humans; Lung Neoplasms; Mice; Mice, Nude; NADPH Oxidases; Protein Transport; Pyrroles; rac1 GTP-Binding Protein; Reactive Oxygen Species; Vascular Endothelial Growth Factor A | 2012 |
Chemoprevention of mouse lung and colon tumors by suberoylanilide hydroxamic acid and atorvastatin.
Topics: Animals; Atorvastatin; Colonic Neoplasms; Dimethylhydrazines; Female; Heptanoic Acids; Histone Deacetylase Inhibitors; Hydroxamic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lung Neoplasms; Mice; Nitrosamines; Pyrroles; RNA, Messenger; Urethane; Vorinostat | 2012 |
Alveolar soft part sarcoma in childhood: is Sunitinib-Sutent® treatment an effective approach?
Topics: Adolescent; Angiogenesis Inhibitors; Child; Combined Modality Therapy; Female; Humans; Indoles; Lung Neoplasms; Pyrroles; Receptor Protein-Tyrosine Kinases; Sarcoma, Alveolar Soft Part; Sunitinib | 2012 |
HGF/c-Met pathway is one of the mediators of sunitinib-induced tumor cell type-dependent metastasis.
Topics: Angiogenesis Inhibitors; Animals; Breast Neoplasms; Cell Line, Tumor; Colorectal Neoplasms; Enzyme-Linked Immunosorbent Assay; Hepatocyte Growth Factor; Humans; Indoles; Lung Neoplasms; Lymphatic Metastasis; Mice; Mice, Nude; Neoplasm Metastasis; Neovascularization, Pathologic; Proto-Oncogene Proteins c-met; Pyrroles; Signal Transduction; Sunitinib | 2012 |
Atorvastatin sensitizes human non-small cell lung carcinomas to carboplatin via suppression of AKT activation and upregulation of TIMP-1.
Topics: Animals; Anticholesteremic Agents; Antineoplastic Agents; Apoptosis; Atorvastatin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Combinations; Drug Resistance, Neoplasm; Drug Synergism; Female; Heptanoic Acids; Humans; Lung Neoplasms; Mice; Mice, Nude; Proto-Oncogene Proteins c-akt; Pyrroles; Tissue Inhibitor of Metalloproteinase-1; Xenograft Model Antitumor Assays | 2012 |
Duocarmycin analogues target aldehyde dehydrogenase 1 in lung cancer cells.
Topics: Aldehyde Dehydrogenase 1 Family; Antineoplastic Agents, Alkylating; Binding Sites; Cell Line, Tumor; Cell Proliferation; Duocarmycins; Humans; Indoles; Isoenzymes; Lung Neoplasms; Pyrroles; Recombinant Proteins; Retinal Dehydrogenase; Tandem Mass Spectrometry | 2012 |
Atorvastatin synergizes with IFN-γ in treating human non-small cell lung carcinomas via potent inhibition of RhoA activity.
Topics: Animals; Antineoplastic Agents; Atorvastatin; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Enzyme Inhibitors; Female; Heptanoic Acids; Humans; Interferon-gamma; Lung Neoplasms; Mice; Organ Specificity; Pyrroles; rhoA GTP-Binding Protein | 2012 |
A case of acute adrenal insufficiency unmasked during sunitinib treatment for metastatic renal cell carcinoma.
Topics: Adrenal Gland Neoplasms; Adrenal Insufficiency; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Lung Neoplasms; Male; Pyrroles; Sunitinib; Thyroid Function Tests; Thyrotoxicosis | 2012 |
Anti-VEGF antibody therapy does not promote metastasis in genetically engineered mouse tumour models.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Animals; Antibodies, Anti-Idiotypic; Disease Models, Animal; Drug Therapy, Combination; Genetic Engineering; Indoles; Kaplan-Meier Estimate; Lung Neoplasms; Mice; Neoplasm Metastasis; Neuroendocrine Tumors; Pancreatic Neoplasms; Proto-Oncogene Proteins p21(ras); Pyrroles; Small Cell Lung Carcinoma; Sunitinib; Vascular Endothelial Growth Factor A | 2012 |
Unusual short-term complete response to two regimens of cytotoxic chemotherapy in a patient with poorly differentiated thyroid carcinoma.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Cisplatin; Combined Modality Therapy; Doxorubicin; Fatal Outcome; Female; Fluorodeoxyglucose F18; Humans; Indoles; Iodine Radioisotopes; Lung Neoplasms; Middle Aged; Niacinamide; Paclitaxel; Phenylurea Compounds; Piperidines; Pyridines; Pyrroles; Quinazolines; Radiopharmaceuticals; Sorafenib; Sunitinib; Thyroid Neoplasms; Thyroidectomy; Tomography, X-Ray Computed | 2012 |
Stimulation of Wnt/ß-catenin pathway in human CD8+ T lymphocytes from blood and lung tumors leads to a shared young/memory phenotype.
Topics: Adoptive Transfer; Apoptosis; Caspase 3; CD8-Positive T-Lymphocytes; Cell Differentiation; Cell Survival; Cells, Cultured; Cytokines; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Lung Neoplasms; Lymphocyte Activation; Phenotype; Proto-Oncogene Proteins c-bcl-2; Pyrimidines; Pyrroles; Stem Cells; Wnt Signaling Pathway | 2012 |
Persistent complete response after single-agent sunitinib treatment in a case of TFE translocation positive relapsed metastatic pediatric renal cell carcinoma.
Topics: Antineoplastic Agents; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Carcinoma, Renal Cell; Child; Female; Humans; Indoles; Kidney Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Neoplasm Recurrence, Local; Prognosis; Pyrroles; Remission Induction; Sunitinib; Tomography, X-Ray Computed; Translocation, Genetic | 2013 |
Structure-based discovery of BM-957 as a potent small-molecule inhibitor of Bcl-2 and Bcl-xL capable of achieving complete tumor regression.
Topics: Animals; Antineoplastic Agents; bcl-X Protein; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Crystallography, X-Ray; Drug Screening Assays, Antitumor; Humans; Lung Neoplasms; Mice; Mice, SCID; Neoplasm Transplantation; Protein Conformation; Proto-Oncogene Proteins c-bcl-2; Pyrroles; Stereoisomerism; Structure-Activity Relationship; Sulfonamides; Tumor Burden | 2012 |
Neoadjuvant targeted therapy in a primary metastasized renal cell cancer patient leads to down-staging of inferior vena cava thrombus (IVC) enabling a cardiopulmonary bypass-free tumor nephrectomy: a case report.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Cardiopulmonary Bypass; Contraindications; Humans; Indoles; Kidney Neoplasms; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoadjuvant Therapy; Nephrectomy; Pyrroles; Sunitinib; Thrombectomy; Thrombosis; Treatment Outcome; Vena Cava, Inferior | 2014 |
Synthesis and docking studies of novel antitumor benzimidazoles.
Topics: Antineoplastic Agents; Benzimidazoles; Breast Neoplasms; Cell Line, Tumor; Drug Screening Assays, Antitumor; Herpesvirus 4, Human; Humans; Lung Neoplasms; MCF-7 Cells; Models, Molecular; Pyrroles; Structure-Activity Relationship; Tetracyclines; Virus Activation | 2012 |
Sarcomatoid non-small cell lung cancer responding to sunitinib.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Follow-Up Studies; Humans; Indoles; Lung Neoplasms; Pyrroles; Sarcoma; Sunitinib; Treatment Outcome | 2013 |
Exfoliative esophagitis in a patient with metastatic renal cell carcinoma during sunitinib treatment.
Topics: Amlodipine; Antihypertensive Agents; Antineoplastic Agents; Aspirin; Carcinoma, Renal Cell; Cyclooxygenase 2 Inhibitors; Esophagitis; Humans; Hypertension; Indoles; Kidney Neoplasms; Lung Neoplasms; Male; Middle Aged; Nephrectomy; Pyrroles; Sunitinib; Tetrazoles; Valine; Valsartan | 2013 |
Gastro-pleuro-pericardial fistula following combined radiation and chemotherapy for lung metastases from renal cell carcinoma: report of a case.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Chemoradiotherapy; Enzyme Inhibitors; Fistula; Gastric Fistula; Heart Diseases; Humans; Indoles; Kidney Neoplasms; Lung Neoplasms; Male; Middle Aged; Pericardium; Pleural Diseases; Protein-Tyrosine Kinases; Pyrroles; Sunitinib; Treatment Outcome | 2013 |
Effective treatment of H838 human non-small cell lung carcinoma with a targeted cytotoxic somatostatin analog, AN-238.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Division; Cytotoxins; Doxorubicin; Humans; Kinetics; Leukocyte Count; Lung Neoplasms; Mice; Mice, Nude; Pyrroles; Transplantation, Heterologous; Tumor Cells, Cultured | 2003 |
SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Carcinoma, Small Cell; Cell Division; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Enzyme Inhibitors; Female; Humans; Imatinib Mesylate; Indoles; Lung Neoplasms; Mice; Mice, Nude; Phosphorylation; Phosphotyrosine; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor beta; Stem Cell Factor; Sunitinib; Tumor Cells, Cultured | 2003 |
The antiangiogenic agent SU5416 down-regulates phorbol ester-mediated induction of cyclooxygenase 2 expression by inhibiting nicotinamide adenine dinucleotide phosphate oxidase activity.
Topics: Angiogenesis Inhibitors; Carcinoma, Non-Small-Cell Lung; Cyclooxygenase 2; Down-Regulation; Drug Interactions; Enzyme Induction; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Indoles; Isoenzymes; Lung Neoplasms; Membrane Proteins; NADPH Oxidases; Prostaglandin-Endoperoxide Synthases; Pyrroles; Superoxides; Tetradecanoylphorbol Acetate | 2003 |
Enhancement of in vivo antitumor activity of classical anticancer agents by combination with the new, glutathione-interacting DNA minor groove-binder, brostallicin.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Colonic Neoplasms; DNA; Doxorubicin; Female; Glutathione; Glutathione Transferase; Guanidines; Irinotecan; Leukemia L1210; Lung Neoplasms; Mice; Mice, Inbred DBA; Mice, Nude; Pyrroles; Transplantation, Heterologous | 2003 |
Combined therapy with direct and indirect angiogenesis inhibition results in enhanced antiangiogenic and antitumor effects.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Animals; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Division; Cell Movement; Cell Survival; Drug Synergism; Endostatins; Endothelium, Vascular; Female; Glioblastoma; Humans; Indoles; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Mice, SCID; Neoplasms; Neovascularization, Pathologic; Prostatic Neoplasms; Pyrroles; Ultrasonography; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2003 |
The multi-targeted kinase inhibitor SU5416 inhibits small cell lung cancer growth and angiogenesis, in part by blocking Kit-mediated VEGF expression.
Topics: Animals; Carcinoma, Small Cell; Drug Resistance, Neoplasm; Female; Humans; Indoles; Lung Neoplasms; Mice; Mice, Nude; Neovascularization, Pathologic; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrroles; Transplantation, Heterologous; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A | 2004 |
Epidermal growth factor receptor tyrosine kinase inhibitor does not improve paclitaxel effect in an orthotopic mouse model of lung cancer.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Animals; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Drug Therapy, Combination; Enzyme Activation; Enzyme Inhibitors; ErbB Receptors; Fibroblast Growth Factor 2; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; Mitogen-Activated Protein Kinases; Models, Animal; Paclitaxel; Phosphorylation; Pyrimidines; Pyrroles; Survival Rate | 2004 |
The insulin-like growth factor-I receptor kinase inhibitor, NVP-ADW742, sensitizes small cell lung cancer cell lines to the effects of chemotherapy.
Topics: Antineoplastic Agents; Apoptosis; Carboplatin; Carcinoma, Small Cell; Cell Division; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Synergism; Enzyme-Linked Immunosorbent Assay; Etoposide; Gene Expression Regulation, Neoplastic; Humans; In Situ Nick-End Labeling; Insulin-Like Growth Factor I; Lung Neoplasms; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Pyrimidines; Pyrroles; Receptor, IGF Type 1; RNA, Messenger; Vascular Endothelial Growth Factor A | 2005 |
Angiogenesis inhibitor Z24 induces endothelial cell apoptosis and suppresses tumor growth and metastasis.
Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Cell Line; Cell Line, Tumor; Colonic Neoplasms; Endothelium, Vascular; Humans; Lung Neoplasms; Male; Mesylates; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms, Experimental; Neovascularization, Pathologic; Pyrroles; Transplantation, Heterologous | 2005 |
Sonographic depiction of changes of tumor vascularity in response to various therapies.
Topics: Angiogenesis Inhibitors; Animals; Combined Modality Therapy; In Situ Nick-End Labeling; Indoles; Lung Neoplasms; Mice; Mice, Inbred C57BL; Neovascularization, Pathologic; Pyrroles; Sunitinib; Ultrasonography, Doppler, Color; Vascular Endothelial Growth Factor A | 2005 |
Cytotoxicity of novel derivatives of the spin trap EMPO.
Topics: Breast Neoplasms; Cell Death; Colonic Neoplasms; Dose-Response Relationship, Drug; Electron Spin Resonance Spectroscopy; Fibroblasts; Free Radicals; Humans; Lung Neoplasms; Pyrroles; Spin Labels; Spin Trapping; Structure-Activity Relationship; Tumor Cells, Cultured | 2006 |
Sunitinib malate.
Topics: Antineoplastic Agents; Carcinoma, Small Cell; Cell Division; Cell Line, Tumor; Disease Progression; Endothelium, Vascular; Enzyme Inhibitors; Gastrointestinal Stromal Tumors; Humans; Indoles; Leukemia, Myeloid; Lung Neoplasms; Pyrroles; Receptor Protein-Tyrosine Kinases; Receptors, Vascular Endothelial Growth Factor; Sunitinib | 2007 |
Effects of vascular endothelial growth factor receptor inhibitor SU5416 and prostacyclin on murine lung metastasis.
Topics: Animals; Carcinoma, Lewis Lung; Cell Adhesion; Cells, Cultured; Disease Progression; Epoprostenol; Indoles; Liver Neoplasms; Lung Neoplasms; Mice; Mice, Inbred C57BL; Neoplasm Metastasis; Neoplasm Transplantation; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Splenic Neoplasms | 2007 |
Sorafenib and sunitinib in the treatment of advanced non-small cell lung cancer.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Humans; Indoles; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2007 |
Selective treatment of cancer: synthesis, biological evaluation and structural elucidation of novel analogues of the antibiotic CC-1065 and the duocarmycins.
Topics: Antibiotics, Antineoplastic; Cell Line, Tumor; Cell Proliferation; Drug Design; Drug Screening Assays, Antitumor; Duocarmycins; Humans; Indoles; Inhibitory Concentration 50; Lung Neoplasms; Molecular Structure; Prodrugs; Pyrroles; Stereoisomerism | 2007 |
Do the results of the new trials change the standard treatment of metastatic renal cell cancer?
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials as Topic; Cytokines; Drug Costs; Humans; Indoles; Kidney Neoplasms; Long-Term Care; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib; Survival Rate | 2007 |
A small molecule pan-Bcl-2 family inhibitor, GX15-070, induces apoptosis and enhances cisplatin-induced apoptosis in non-small cell lung cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Cisplatin; Dose-Response Relationship, Drug; Drug Synergism; ErbB Receptors; Humans; Immunoprecipitation; Indoles; Lung Neoplasms; Neoplasm Proteins; Proto-Oncogene Proteins c-bcl-2; Pyrroles; Tetrazolium Salts; Thiazoles | 2008 |
[Chronic lymphocytic leukemia and loss of strength in the right arm--not a typical combination].
Topics: Administration, Oral; Aged; Antineoplastic Agents; Arm; Benzenesulfonates; Bone Neoplasms; Carcinoma, Renal Cell; Clinical Trials, Phase III as Topic; Disease Progression; Humans; Hypesthesia; Indoles; Kidney Neoplasms; Leukemia, Lymphocytic, Chronic, B-Cell; Liver Neoplasms; Lung Neoplasms; Magnetic Resonance Imaging; Male; Muscle Weakness; Neoplasms, Second Primary; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Radiography, Abdominal; Radiography, Thoracic; Risk; Risk Factors; Sex Factors; Sorafenib; Splenic Neoplasms; Sunitinib; Time Factors; Tomography, X-Ray Computed | 2007 |
Complete cerebral response with sunitinib for metastatic renal cell carcinoma.
Topics: Aged; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Lung Neoplasms; Magnetic Resonance Imaging; Male; Neoplasm Recurrence, Local; Pyrroles; Sunitinib | 2007 |
Potential role of multi-targeted tyrosine kinase inhibitors in non-small-cell lung cancer.
Topics: Angiogenesis Inducing Agents; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Humans; Indoles; Lung Neoplasms; Protein Kinase Inhibitors; Pyrroles; Receptor Protein-Tyrosine Kinases; Sunitinib; Treatment Outcome | 2007 |
Synthesis, SAR, and Evaluation of 4-[2,4-Difluoro-5-(cyclopropylcarbamoyl)phenylamino]pyrrolo[2,1-f][1,2,4]triazine-based VEGFR-2 kinase inhibitors.
Topics: Animals; Cell Line, Tumor; Cyclopropanes; Cytochrome P-450 Enzyme Inhibitors; Endothelial Cells; Humans; Lung Neoplasms; Mice; Mice, Nude; Oxadiazoles; Protein Kinase Inhibitors; Pyrroles; Structure-Activity Relationship; Triazines; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2008 |
Inhibition of proliferation of small intestinal and bronchopulmonary neuroendocrine cell lines by using peptide analogs targeting receptors.
Topics: Apoptosis; Bronchial Neoplasms; Carcinoid Tumor; Caspase 3; Cell Cycle; Cell Proliferation; Cytotoxins; Doxorubicin; Flow Cytometry; Gonadotropin-Releasing Hormone; Growth Hormone-Releasing Hormone; Humans; Intestinal Neoplasms; Intestine, Small; Ki-67 Antigen; Lung Neoplasms; Pyrroles; Receptors, LHRH; Receptors, Somatostatin; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured | 2008 |
Prolonged complete responses and near-complete responses to sunitinib in metastatic renal cell carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pyrroles; Sunitinib; Time Factors | 2007 |
Acute cardiac failure after sunitinib.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Fatal Outcome; Heart Failure; Humans; Indoles; Kidney Neoplasms; Lung Neoplasms; Male; Middle Aged; Pyrroles; Sunitinib | 2008 |
Rare case of hemangiopericytoma responds to sunitinib.
Topics: Angiogenesis Inhibitors; Bone Neoplasms; Hemangiopericytoma; Humans; Indoles; Lung Neoplasms; Male; Maxillary Sinus Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Neovascularization, Pathologic; Pelvic Neoplasms; Protein Kinase Inhibitors; Pyrroles; Radiography; Rare Diseases; Sunitinib | 2008 |
Discovery of brivanib alaninate ((S)-((R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-yl)2-aminopropanoate), a novel prodrug of dual vascular endothelial growth factor receptor-2 and fibroblast growth fa
Topics: Administration, Oral; Alanine; Animals; Biological Availability; Carcinoma; Cell Proliferation; Clinical Trials, Phase II as Topic; Drug Design; Drug Evaluation, Preclinical; Humans; Intestines; Liver; Lung Neoplasms; Mice; Microsomes; Molecular Structure; Prodrugs; Protein Kinase Inhibitors; Pyrroles; Receptor, Fibroblast Growth Factor, Type 1; Solubility; Stereoisomerism; Triazines; Vascular Endothelial Growth Factor Receptor-2; Water; Xenograft Model Antitumor Assays | 2008 |
LY2109761, a novel transforming growth factor beta receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis.
Topics: Animals; Anoikis; Antimetabolites, Antineoplastic; Apoptosis; Cell Movement; Deoxycytidine; Drug Therapy, Combination; Gemcitabine; Humans; Lung Neoplasms; Mice; Mice, Inbred C57BL; Mice, Nude; Neoplasm Invasiveness; Neovascularization, Pathologic; Pancreatic Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyrazoles; Pyrroles; Receptor, Transforming Growth Factor-beta Type I; Receptor, Transforming Growth Factor-beta Type II; Receptors, Transforming Growth Factor beta; Ribonucleotide Reductases; Signal Transduction; Smad2 Protein; Survival Rate; Transforming Growth Factor beta; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2008 |
Activity of bis-carbamoyloxymethyl derivatives of pyrroles and pyrrolizines against human tumor xenografts in nude mice.
Topics: Adenocarcinoma; Animals; Breast Neoplasms; Carcinoma, Small Cell; Cell Line; Colonic Neoplasms; Drug Evaluation, Preclinical; Humans; Lung Neoplasms; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms; Neoplasms, Experimental; Pyrroles; Pyrrolidines; Transplantation, Heterologous | 1982 |
Antioxidant therapy for coronary artery disease: don't paint the walls without treating the termites!
Topics: Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Antioxidants; Atorvastatin; Cholesterol, LDL; Coronary Disease; Heptanoic Acids; Humans; Lung Neoplasms; Oxidation-Reduction; Prospective Studies; Pyrroles; Randomized Controlled Trials as Topic; Risk; Survival Analysis; Treatment Outcome; Vitamin A; Vitamin E | 1999 |
Pyrronamycin A and B, novel antitumor antibiotics containing pyrrole-amide repeating unit, produced by Streptomyces sp.
Topics: Animals; Antibiotics, Antineoplastic; Antiviral Agents; Carcinoma; Distamycins; Fermentation; Humans; Lung Neoplasms; Mice; Mice, Nude; Microbial Sensitivity Tests; Pyrroles; Sarcoma 180; Streptomyces; Structure-Activity Relationship | 2000 |
Clinical strategy for the development of angiogenesis inhibitors.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Decision Making; Disease Progression; Drug Evaluation; Drug Resistance, Neoplasm; Drugs, Investigational; Endothelial Growth Factors; Enzyme Inhibitors; Humans; Indoles; Lung Neoplasms; Lymphokines; Protein Isoforms; Protein-Tyrosine Kinases; Pyrroles; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2000 |
Inhibition of metastatic renal cell carcinomas expressing somatostatin receptors by a targeted cytotoxic analogue of somatostatin AN-238.
Topics: Animals; Antibiotics, Antineoplastic; Carcinoma, Renal Cell; Cell Division; Doxorubicin; Humans; Kidney Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Mice; Mice, Nude; Microsatellite Repeats; Neoplasm Transplantation; Pyrroles; Receptors, Somatostatin; Reverse Transcriptase Polymerase Chain Reaction; Time Factors; Tumor Cells, Cultured | 2000 |
A targeted cytotoxic somatostatin (SST) analogue, AN-238, inhibits the growth of H-69 small-cell lung carcinoma (SCLC) and H-157 non-SCLC in nude mice.
Topics: Animals; Antibiotics, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cell Division; Doxorubicin; Lung Neoplasms; Male; Mice; Mice, Nude; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger | 2001 |
Indolinone tyrosine kinase inhibitors block Kit activation and growth of small cell lung cancer cells.
Topics: Animals; Carcinoma, Small Cell; Cell Division; CHO Cells; Cricetinae; Dose-Response Relationship, Drug; Enzyme Activation; Enzyme Inhibitors; Growth Inhibitors; Humans; Indoles; Lung Neoplasms; Models, Molecular; Oxindoles; Phosphorylation; Propionates; Proto-Oncogene Proteins c-kit; Pyrroles; Receptor Protein-Tyrosine Kinases; Receptors, Platelet-Derived Growth Factor; Stem Cell Factor; Structure-Activity Relationship; Tumor Cells, Cultured | 2001 |
Vascular endothelial growth factor-mediated angiogenesis inhibition and postoperative wound healing in rats.
Topics: Angiogenesis Inhibitors; Animals; Endothelial Growth Factors; Endothelium; Indoles; Lung Neoplasms; Lymphokines; Male; Models, Animal; Neovascularization, Physiologic; Pneumonectomy; Pyrroles; Rats; Rats, Sprague-Dawley; Regional Blood Flow; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors; Wound Healing | 2002 |
Effects of some pyrrolic and dihydropyrrolizine esters on mouse skin: a preliminary study.
Topics: Alkylating Agents; Animals; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Neoplasms, Experimental; Pyrroles; Pyrrolizidine Alkaloids; Skin Neoplasms; Structure-Activity Relationship | 1979 |
Novel pyrrolo[2,3-d]pyrimidine antifolates: synthesis and antitumor activities.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Line; Chemical Phenomena; Chemistry; Folic Acid Antagonists; Humans; Lung Neoplasms; Pyrimidines; Pyrroles; Structure-Activity Relationship | 1991 |